Interaction	Notes	Reference

IL-1α and IL-1β induce autophagy	Induction of autophagy by IL-1 family cytokines suggests a potential negative feedback loop for the control of inflammation by autophagy, as well as a possible anti-microbial response mediated by inflammatory cytokines	Shi and Kehrl (2010)

Inhibition of autophagy increases IL-1α, IL-1β, and IL-18 secretion	Inhibition of (or deficiency in) autophagy leads to increased secretion of IL-1 family cytokines in response to TLR ligands and Mycobacterium tuberculosis. This is dependent on TRIF (in mice), reactive oxygen species, and mitochondrial DNA. These results suggest that autophagy normally regulates endogenous factors that would otherwise induce inflammasome assembly, caspase-1 activation, and subsequent processing and secretion of IL-1β and IL-18. In humans, regulation of IL-1β by autophagy occurs at the transcriptional level	Saitoh et al. (2008), Crisan et al. (2011), Harris et al. (2011), Kleinnijenhuis et al. (2011), Nakahira et al. (2011), Zhou et al. (2011a)

Induction of autophagy reduces IL-1β secretion in vitro and in vivo	Induction of autophagy with drugs (e.g., rapamycin) or starvation reduces secretion of IL-1β by macrophages and dendritic cells in response to LPS with alum or ATP or in response to Mycobacterium tuberculosis. Induction of autophagy also decreases intracellular levels of pro-IL-1β. In a mouse model of LPS-induced sepsis, rapamycin decreases serum levels of IL-1β.	Crisan et al. (2011), Harris et al. (2011), Shi et al. (2012)

Autophagosomes sequester and degrade IL-1β and inflammasome components	In macrophages stimulated with TLR ligands, autophagosomes sequester IL-1β. The inflammasome component ASC is ubiquitinated in response to inflammasome activation and delivered to autophagosomes. NLRP3 and AIM2 are also sequestered by autophagosomes	Harris et al. (2011), Shi et al. (2012)

Activation of the NLRP3 and AIM2 inflammasomes induces autophagosome formation	Induction of the AIM2 inflammasome by transfection of macrophages with poly(dA:dT) or the NLRP3 inflammasome with uric acid crystals or nigericin leads to an increase in autophagosome formation	Shi et al. (2012)

Autophagy can act as secretory pathway for the release of IL-1β	Induction of inflammasome activation in parallel with autophagy induction can lead to an increase in IL-1β secretion. This novel secretory pathway is dependent on inflammasome assembly, Atg5, Rab8a, and GRASP55 (GORASP2; a mammalian Golgi reassembly stacking protein paralog)	Dupont et al. (2011)


First Author Year (Ref)	Study Years	AA, n 	Caucasian, n 	Age, yrs	Population	Study design	Enrollment states

Marcus et al. 2010 [7]	1989-1999	804	4,543	>65	Older population	Cohort	15 U.S. states**, Washington D.C.

Go et al. 2001 [16]	1996-1997	39,579	519,714	>50*	General population	Cross-sectional	California

Alonso et al. 2009 [17]	1987–2004	4,115	11,292	>55*	General population	Cohort	Maryland,

							Minnesota,

							Mississippi,

							N. Carolina

Afzal et al. 1999 [18]	1996	113	50	>35*	Heart failure	Cohort	Michigan

Ruo et al. 2004 [19]	1999-2000	223	1,150	>35*	Heart failure	Cohort	California

Winkelmayer et al. 2011 [20]	1992–2006	90,217	121,698	>30*	Hemodialysis	Cohort	United States

Upshaw Jr. 2002 [21]	1996–1998	922	1,201	>20	Hospitalized patients	Cohort	Georgia

Shen et al. 2010 [22]	2008	40,293	191,860	>60	Older population	Cross-sectional	California

Smith et al. 2006 [23]	1993–2005	644	1,932	>25*	Post-CABG	Case control	Ohio

Lahiri et al. 2011 [24]	2004–2008	270	731	>25*	Post-CABG	Cohort	Michigan


Indicators	Prevalence per 10,000 (n/N)*	95 % CI

Prevalence of congenital defects	52.0 (142/27201)	44.0–61.0

Prevalence of selected NTDs only	4.0 (11/27201)	2.0–7.0

Prevalence of other congenital defects except NTDs	48.0 (131/27201)	40.0–57.0

Prevalence of congenital defects in Mountain	16.0 (5/3079)	7.0–38.0

Prevalence of congenital defects in Hill	56.0 (85/15156)	45.0–69.0

Prevalence of congenital defects in Terai	58.0 (52/8966)	44.0–76.0


Variable	Frequency	%

Age (mean = 36.8 ± 14.0 yrs)

< 50 years	554	80

≥ 50 years	139	20

Gender

Male	374	54

Female	319	46

Religion

Christian	554	80

Moslem	111	16

Traditional religion	21	3

Other	7	1

Marital status

Married	267	38

Single	281	41

Widowed	68	10

Separated	50	7

Divorced	27	4

Highest education attained

Illiterate	97	14

Primary	104	15

Secondary	360	52

Tertiary	132	19

Monthly income (Cedis)

< 100	180	26

100-999	270	39

1000-1999	21	3

2000-2999	14	2

≥ 3000	14	2

Unemployed	194	28

Stroke risk factors

Alcohol intake	118	17

Hypertension	76	11

Smoking	47	7

Previous stroke	43	6

High cholesterol	25	4

Heart disease	19	3

Diabetes	17	2

At least one stroke risk factor	274	40


Method	Detection range	Reference

Colorimetric	0.05–50 ng/mL	Luan et al., 2015

Surface plasmon resonance	0–10 ng/mL	Zhu et al., 2015

Colorimetric	0.5–100 ng/mL	Wang et al., 2016a

Colorimetric	0.0316–316 ng/mL	Our work


Variable	De Hoogte(n = 90)	Corpus-Noord(n = 133)	F	p	ηp2

Neighborhood Satisfaction (1–5)	3.39 (0.07)	3.88 (0.07)	26.12	<0.001	0.11

Well-Being (Happiness; 0–10)	7.24 (0.14)	7.34 (0.11)	0.34	0.563	0.00

Green Space Quality (1–5; average score)	3.21 (0.07)	3.61 (0.06)	20.04	<0.001	0.08

Green spaces in my neighborhood

1. contain enough recreational facilities (e.g., play equipment, hard court, grass pitches for football).	3.10 (0.11)	3.39 (0.09)	4.13	0.043	0.02

2. provide amenities for sitting, picnic table, litter bins, signs and lighting in the night.	2.74 (0.11)	3.37 (0.09)	18.16	<0.001	0.08

3. have good natural features such as grass, trees and flower beds.	3.37 (0.09)	3.87 (0.07)	17.71	<0.001	0.08

4. are absent of incivilities (e.g., general litter, graffiti, dog mess, evidence of alcohol, drug use, broken glass and noise).	2.95 (0.11)	3.40 (0.09)	10.15	0.002	0.04

5. are easily accessed, there are many access points and enough walking paths, and roads around are not busy.	3.64 (0.08)	3.91 (0.06)	7.36	0.007	0.03

6. are well maintained.	3.47 (0.11)	3.73 (0.09)	3.46	0.06	0.02

Beneficial Affordances of Green Space (1–5; average score)	4.00 (0.08)	3.98 (0.06)	0.05	0.824	0.00

Green spaces in my neighborhood

1. promote the quality of life.	4.12 (0.08)	4.16 (0.07)	0.08	0.779	0.00

2. promote health.	4.12 (0.08)	4.06 (0.07)	0.37	0.544	0.00

3. promote recreational use.	3.90 (0.10)	4.01 (0.08)	0.68	0.411	0.00

4. promote social interaction.	3.86 (0.10)	3.69 (0.08)	1.55	0.214	0.01


TLD placement	Cumulative mSv	mSv per screw	% Reduction

	Robot-Guided (154 screws)	Fluoro-Guided (140 screws)	Robot-guided	Fluoro-guided

Outside of thyroid protector	1.24	3.15	0.0082	0.0225	63.7%

Inside of thyroid protector	0.91	1.95	0.0060	0.0139	56.9%

Outside of trunk protector	1.37	3.35	0.0090	0.0239	62.3%

Inside of trunk protector	0.84	1.84	0.0055	0.0131	57.8%

Eye dosimeter	0.71	2.31	0.0047	0.0165	71.6%


Identification criteria

Cardiovascular dysfunction	• Shock

	• Use of continuous vasoactive drugs

	• Cardiac arrest

	• Cardio-pulmonary resuscitation

	• Severe hypoperfusion (lactate > 5 mmol/L or > 45 mg/dL)

	• Severe acidosis (pH < 7.1)

Respiratory dysfunction	• Acute cyanosis

	• Gasping

	• Severe tachypnea (respiratory rate > 40 bpm)

	• Severe bradypnea (respiratory rate < 6 bpm)

	• Severe hypoxemia (PAO2/FiO2 < 200 or O2 saturation < 90 % for ≥60 min)

	• Intubation and ventilation not related to anesthesia

Renal dysfunction	• Oliguria non responsive to fluids/diuretics

	• Dialysis for acute renal failure

	• Severe acute azotemia (creatinine ≥ 300 umol/ml or ≥ 3.5 mg/dL)

Coagulation/hematologic dysfunction	• Failure to form clots

	• Massive transfusion of blood or red cells (≥5 units)

	• Severe acute thrombocytopenia (<50,000 platelets/ml)

Hepatic dysfunction	• Jaundice in the presence of pre-eclampsia

	• Severe acute hyperbilirubinemia (bilirubin > 100 umol/L or > 6.0 mg/dL)

Neurologic dysfunction	• Prolonged unconsciousness (lasting ≥ 12 hours)/coma (including metabolic coma)

	• Stroke

	• Status epilepticus/uncontrollable fits

	• Total paralysis

Uterine dysfunction	• Hemorrhage or infection leading to hysterectomy


Patient	Sex	Age (years)	Time from implantation until removal (months)	Implant Material	Location	Reason for removal	Broken Screws?

1	Female	48	11	Ti	PU	Nonunion	No

2	Female	27	23	Ti	DH	Symptoms	Yes

3	Female	34	5	Ti	PU	Infection	No

4	Male	40	48	SS	DH	Contracture	No

5	Male	30	74	SS	PU	Infection	No

6	Female	25	38	Ti	Both	Nonunion	No

7	Male	44	2	Ti	Both	Infection	No

8	Female	43	5	SS	PU	Symptoms	No

9	Female	30	12	Ti	PU	Symptoms	No

10	Female	57	9	Ti	PU	Symptoms	No

11	Female	46	33	SS	Both	Nonunion	No

12	Male	24	8	SS	PU	Infection	No

13	Male	47	4	Ti	DH	Infection	No

14	Female	40	9	SS	Both*	Symptoms	Yes

15	Male	17	53	Ti	Both*	Nonunion	Yes

16	Male	56	25	Ti	DH	Symptoms	Yes

17	Female	35	64	Ti	DH	Infection	Yes

18	Female	48	12	Ti	PU	Symptoms	No

19	Male	27	8	SS	DH	Infection	No

20	Male	66	16	Ti	PU	Nonunion	Yes

21	Male	28	7	Ti	Both	Nonunion	No


Concrete resistivity ρ (kΩcm)	Probable corrosion rate

>20	Despicable

Between 10 and 20	Low

Between 5 and 10	High

<5	Very high


Target virusesa	Target genesb	Primer sequence, 5′–3′c	Size (bp)	Source or reference

PToV	S	F: ACCCCTGCCTGAGGTTTCYTTR: AGCACGACGTTGTCTRCGTGT	451	Established by our own laboratory

PEDV	S	F: TTCTGAGTCACGAACAGCCAR: CATATGCAGCCTGCTCTGAA	651	Kim et al. (2001) [11]

PKBV	3D	F: TGGATTACAAGTGTTTTGATGCR: TGTCGTAGAACTCCTTGATGAA	313	Established by our own laboratory

 PRV A	 VP6	F: AAAGATGCTAGGGACAAAATTGR: TTCAGATTGTGGAGCTATTCCA	308	 Elschner et al. (2002) [12]

nF: GACAAAATTGTCGAAGGCACATTATAnR: TCGGTAGATTACCAATTCCTCCAG	121

PRV B	NSP2	F: CTATTCAGTGTGTCGTGAGAGG R: GCAGACAAGCTAGCCCGCTTCG	434	Gouvea et al. (1991) [13]

 PRV C	VP6	F: CTCGATGCTACTACAGAATCAGR: AGCCACATAGTTCACATTTCATCC	366	 Gouvea et al. (1991) [13]

nF: CTCGATGCTACTACAGAATCAGnR: GGGATCATCCACGTCATGCGT	328

TGEV	ORF1b	F: GGGTAAGTTGCTCATTAGAAATAATGGR: CTTCTTCAAAGCTAGGGACTG	1006	Kim et al. (2010) [14]

S

AV	RdRp	F11: GARTTYGATTGGRCKCGKTAYGAF12: GARTTYGATTGGRCKAGGTAYGAF21: CGKTAYGATGGKACKATHCF22: AGGTAYGATGGKACKATHCR1: GGYTTKACCCACATICCRAA	422	Chu et al. (2008) [15]

 MRV	L1	F: GCATCCATTGTAAATGACGAGTCTGR: CTTGAGATTAGCTCTAGCATCTTCTG	416	 Decaro et al. (2005) [16]

nF: GCTAGGCCGATATCGGGAATGCAGnR: GTCTCACTATTCACCTTACCAGCAG	344

PSaV and PNoV	RdRp	F: GATTACTCCAAGTGGGACTCCACR: TGACAATGTAATATCACCATA	319	Kim et al. (2010) [14]


Correlation between IGF-I/IGFBP-3 molar ratio and:	Total group (GHD and controls)	GHD group

Height SDS	+0.01	+0.16

BMI SDS for HA	+0.26	+0.24

Ghrelin	−0.35∗	−0.34∗

Leptin	+0.29	+0.34

Adiponectin	−0.15	−0.41∗

Resistin	−0.24	0.0

Triglycerides	+0.4∗	+0.59∗

Cholesterol	+0.22	+0.05

LDL-cholesterol	+0.16	+0.08

HDL-cholesterol	−0.04	−0.59∗

Glucose	+0.18	+0.2

Insulin	+0.41∗	+0.48∗

IRI HOMA	+0.36∗	+0.41∗


Characteristics	Value

No.	%

Material surrounding the base

Mud	10	40

Brick	2	8

Small amount of cement	2	8

Large cement platform	11	44

Tubewell colour

Natural	21	84

Green	3	12

Red	1	4

Sediment in water

Iron	0	0

Sand	1	4

Iron and sand	3	13

None	21	84

Arsenic present∗

No (<50 μg/L)	2	8

Yes (≥50 μg/L)	2	8

Never tested	21	84

	Mean (SD) and range

Temperature (°C)	26.8 (0.5)

	25.8-28.6

pH	7.3 (0.3)

	6.5-7.8

	Median (IQR) and range

Total iron concentration (mg/L)

AAS	11.4 (8.4-15.8)

	0.2-28.0

Test-kit	12.8 (10.8-18.8)

	0.6-32.0

Colorimeter	13.60 (9.60-17.60)

	0.50-49.20

Ferrous iron by colorimeter (mg/L)	6.32 (3.10-10.50)

	0.02-28.60


Organism	Fe' (Free Inorganic Iron)	FOB	FeAB

Not Limited	Fe-Limited	Fe-Limited	Fe-Limited

Synechococcus WH8102	Yes (+)	Yes (+++)	Yes (++)	n/a

Synechococcus WH7803	Yes (+++)	Yes (+++)	Yes (++)	n/a

Synechococcus CCMP1183	Yes (++)	-	-	-

Synechococcus PCC7002	Yes (++)	Yes (+++)	Yes (+)	No

Prochlorococcus MED4	Yes (++)	Yes (+++)	Yes (+)	n/a

Synechocystis PCC6803	Yes (+++)a	Yes (+++)a	Yes (++)a	Yes (++)

Trichodesmium IMS101	-	Yes (+)	-	-

Anabaena UTEX2576	Yes (+++)	Yes (+++)	No*	No


Parameter	Insufficient Sleep	Excessive Duration

	OR	95% CI	p-Value	OR	95% CI	p-Value

Hospital capacity/quality

High vs. Low	0.99	(0.72, 1.38)	0.979	1.05	(0.72, 1.52)	0.812

Medium vs. Low	0.33	(0.21, 0.54)	<0.000	2.57	(1.69, 3.90)	<0.000

Residence

Urban vs. Rural	-	-	-	0.64	(0.50, 0.83)	0.001

Nationality

Minority vs. Han nationality	0.45	(0.24, 0.84)	0.012	-	-	-

Without sibling

Yes vs. No	0.8	(0.65, 0.97)	0.024	-	-	-

Education level

Secondary education vs. Basic education	1.32	(0.93, 1.86)	0.117	-	-	-

Higher education vs. Basic education	0.96	(0.73, 1.27)	0.797	-	-	-

Trimester of pregnancy

Second trimester of pregnancy vs. First trimester of pregnancy	0.66	(0.49, 0.90)	0.009	1.08	(0.74, 1.57)	0.705

Third trimester of pregnancy vs. First trimester of pregnancy	0.65	(0.49, 0.86)	0.003	1.51	(1.07, 2.13)	0.020

Job

Manual vs. Non-manual	-	-	-	1.19	(0.86, 1.64)	0.289

Unemployed vs. Non-manual	-	-	-	1.46	(1.13, 1.88)	0.003

Others vs. Non-manual	-	-	-	1.19	(0.86, 1.66)	0.296

Secondhand smoke exposure frequency per week

Every day vs. None	1.43	(1.10, 1.86)	0.008	-	-	-

4–6 days per week vs. None	1.1	(0.73, 1.66)	0.637	-	-	-

1–3 days per week vs. None	1.44	(1.14, 1.80)	0.002	-	-	-

Gestational diabetes mellitus

Yes vs. No	1.51	(0.94, 2.43)	0.085	-	-	-


Coded value	Glasgow coma scale score	Systolic blood pressure (mmHg)	Respiratory rate (/min)	Age (years)	Injury Severity Score

4	13-15	> 89	10-29		< 16

3	9-12	76-89	> 29		16-24

2	6-8	50-75	6-9		25-40

1	4-5	1-49	1-5	≥ 55	41-65

0	< 4	No pulse	0	0-54	> 65


Grade	Points	Symptoms of neurological behavior

Normal (no neurological deficit)	0	Rats behave normally, can fully outstretch forelimbs toward the ground when lifting tails and dangling.

Mild neurological deficit	1	Rats cannot fully stretch their left forelimbs when lifting tails and dangling.

Moderate neurological deficit	2	Rats have decreased resistance to lateral push and mild neurological behavior.

Severe neurological deficit	3	Rats turn around into a circle, and have mild and moderate neurological behavior.

4	Rats do not walk spontaneously and have a depressed level of consciousness.


	LD 14:10 No Wheels	LDLD 7:5:7:5 Wheels (1)	LDLD 7:5:7:5 Wheels (2)	LDLD 7:5:7:5 No Wheels	LDLD 9:3:9:3 No Wheels (1)	LDLD 9:3:9:3 No Wheels (2)

General Locomotion (GL)	0	1/17	13/18	6/18	8/17	10/14

Body Temperature (Tb)	0	1/17	13/18	6/18	7/16	10/14


Group	Resistive Index before sildenafil	Resistive Index after sildenafil

	Control	Breath hold	Hyperventilation	Control	Breath hold	Hyperventilation

Normal	0.56 ± 0.02	0.51 ± 0.02*	0.7 ± 0.03*	0.58 ± 0.02	0.49 ± 0.02*	0.7 ± 0.02*

DM	0.6 ± 0.02	0.53 ± .02*	0.71 ± 0.02*	0.6 ± .015	0.53 ± .02*	0.72 ± .018*


	max ATP	max NADH	max NADPH

Dissimilation processes	in mol.mol(methanol)-1

MeOH - > CO2 (cytoplasmic FDH)	5	2	2

MeOH - > CO2 (periplasmic FDH)	3	0	0

MeOH + CO2 (Ser cycle) - > Acetyl-CoA - > TCA cycle - > 2 CO2	1	0.5	0.5

MeOH + n CO2 (Ser cycle + EMCP) - > other C2s, C3s, etc - > central pathways - > n+1 CO2	1	0.5	0.5


	Mean (SD)	n	t-value

Pretest	Posttest

1. Teamwork and collaboration**	3.89 (0.52)	4.02 (0.56)	676	7.687

2. Negative professional identity*	2.33 (0.79)	2.27 (0.86)	691	−2.178

3. Positive professional identity**	3.74 (0.57)	3.87 (0.60)	692	6.409

4. Roles and responsibilities**	3.24 (0.49)	3.31 (0.69)	695	3.503


Factors	Subgroup	N	%

Median age at baseline		69.9 y (45–70)

Sex	Male	6	60

Female	4	40

Smoker	Yes	5	50

No	2	20

Unknown	3	30

ECOG PS	0-1	10	100

2	0	0

Histopathology	Adenocarcinoma	9	90

Squamous cell	1	10

Mutational status	EGFR mutation	0	0

ALK translocation	1	10

ROS1 translocation	1	10

None	8	80

Metastasis location	Bone	1	10

Liver	1	10

Contralateral lung	4	40

Adrenal gland	1	10

Brain	3	30

Chemotherapy	CDDP-pemetrexed	7	70

CDDP-gemcitabine	2	20

CDDP-taxotere	1	10


Screening strategya	B-coefficient	β-coefficient	P-value	Adjusted R2

Death reduction, %b

 Japan	initiating agesc	−0.696	−0.771	0.000***	0.93

 	terminating agesd	0.598	0.497	0.000***

 United States	initiating ages	−0.401	−0.473	0.000***	0.95

 	terminating ages	0.900	0.797	0.000***

Average life expectency extension, %b

 Japan	initiating ages	−1.078	−0.932	0.000***	0.93

 	terminating ages	0.287	0.186	0.052

 United States	initiating ages	−0.829	−0.835	0.000***	0.93

 	terminating ages	0.526	0.398	0.002**


Location		Number of samples	Standardized mean (μg/m3)	95% Confidence interval

Bedroom	Urban cement roof	30	116	87.8 to 144

Urban tiled roof	12	233	133 to 333

Urban straw roof	4	134	109 to 159

Rural cement roof	19	175	134 to 217

Rural tiled roof	22	125	50.6 to 199

Rural straw roof	9	236	120 to 351

Combined roof urban	47	166	117 to 215

Combined roof rural	50	192	135 to 249

Veranda	Urban	15	592	281 to 902

Rural	16	445	264 to 627

School	Urban	14	121	82.4 to 160

Rural	8	123	37.5 to 209

Outdoors	Urban	19	131	80.7 to 181

Rural	19	202	128 to 276

Kitchen cooking	Biomass together	21	908	614 to 1203

Non-biomass	10	175	63.2 to 286

Kitchen no cooking	Biomass	21	438	− 138 to 1010

Non-biomass	8	213	− 15.8 to 442


Abbreviation	Corresponding pathological diagnosis

NILM	normal, infection, inflammation, lichen planus, leukoplakia, benign epithelial lesion, etc.

LSIL	mild and moderate dysplasia, and SIN1 and SIN2; mentioned in WHO 2005

HSIL	severe dysplasia, carcinoma in situ, and SIN3; mentioned in WHO 2005

SCC	squamous cell carcinoma

Other malig.	other malignancy

IFN	indefinite for neoplasia or non-neoplasia


Plasmids	β-Galactosidase Activity in units/mg bacteria	Protein Functions

Negative Control

pT18 + pT25	412.0 ± 82.4	pT18: Empty vector

Positive Control:		pT25: Empty vector

pT18-PknD + pT25-CdsD-FHA-2	996.3 ± 50.0	FliI: Putative flagellar ATPase

Negative Interactions:		FliF: Putative flagellar MS ring protein

pT18-FliI + pT25-FliF	396.4 ± 32.1	FlhA: Putative flagellar integral membrane

pT18-FliF + pT25-Cpn0859	421.1 ± 25.9	protein

pT18-FliI + pT25-Cpn0706	404.4 ± 19.5	Cpn0859: Hypothetical C. pneumoniae

pT18-Cpn0706 + pT25-FlhA	443.0 ± 32.3	protein

Positive Interactions:		Cpn0706: Putative T3S chaperone

pT18-FliF + pT25-FlhA	847.2 ± 21.2	CdsL: Putative T3S ATPase tethering

pT18-FliI + pT25-FlhA	942.9 ± 123.1	protein

pT18-FliI + pT25-CdsL	874.3 ± 59.3	CopN: Putative T3S plug protein

pT18-FliI + pT25-CopN	943.2 ± 74.2	Cpn0322: Putative CdsU ortholog

pT18-Cpn0322 + pT25-FlhA	779.9 ± 32.7

pT18-CdsL + pT25-FlhA	832.1 ± 23.3


	Data set 1	Data set 2	Data set 3	Data set 4

Selection method:	Back	For	Back	For	Back	For	Back	For

Slope

Temperature	+	+	+	+	+	+	+	+

Precipitation

Market influence	+	+	+	+	+	+	+	+

Population density 							+

Built-up area	+	+	+		+	+

Distance to roads

Wetland area	-	-	-	-	-	-	-	-

Cropland area			+	+	+	+

Organic content

Regulatory Quality

ROC	0.908	0.908	0.884	0.880	0.905	0.905	0.908	0.887


Patient no.	1	2	3	4	5	6	7

Isolated organism	Pseudomonas aeruginosa	Pseudomonas aeruginosa	Pseudomonas aeruginosa	Klebsiella pneumoniae	Klebsiella pneumoniae	Pseudomonas aeruginosa	Pseudomonas aeruginosa

Site of isolation	Bronchial secretions	Cerebrospinal fluid	Bronchial secretions	Tip of central venous catheter	Bronchial secretions	Urine	Blood

Date of isolation (mo/dd/year)	08/07/2001	07/17/2002	07/29/2003	01/16/2004	01/30/ 2004	04/16/ 2004

Days in the ICU until the isolation of the pandrug-resistant strain	40	62	34	33	52	32	0

Prior colistin use (days)	0	23	11	33	31	6	0

Antibiotic combination used after isolation	Colistin + imipenem/ cilastatin, Colistin + meropenem, Colistin + ofloxacin	Two days prior to the isolation, all antibiotics had been stopped	Colistin + meropenem + ofloxacin + gentamicin	Colistin + meropenem	Colistin + ampicillin/sulbactam + trimethoprim/sulfamethoxazole	Colistin + ceftazidime	Piperacillin/tazobactam

Dosage/Duration of colistin	2 million IU q8h iv for 35 days, 1 million IU q8h iv for 17 days	1 million IU q8h iv for 23 days	3 million IU q8h iv for 37 days, 1 million IU q8h nebulized for 11 days	2 million IU q8h iv for 16 days, 1 million IU q8h iv for 12 days, 1 million IU q12h iv for 19 days	1 million IU q8h iv for 34 days	2 million IU q8h in for 35 days, 1 million IU q8h iv for 17 days	2.25 gr q8h iv for 10 days

Outcome of the infection	Cure (clinical + microbiological).	No response.Patient died due to meningitis.	Cure (clinical + microbiological).	Clinical cure (microbiological persistence for 1 month).	Deterioration.Superinfection of the respiratory tract by an Acinetobacter baumannii strain. Patient died due to sepsis.	Cure (clinical + microbiological).	Cure (clinical + microbiological).


Population	Location	Insecticide	N	% Mortality [Cl95]	Resistance status

Sites

Banikoara	West-North	DDT	100	4 [−3.68-11.68]	R

Permethrin	100	4 [−3.68-11.68]	R

Deltamethrin	100	28 [10.40- 45.60]	R

Bendiocarb	100	52 [32.42- 71.58]	R

Kandi	West-North	DDT	100	12 [− 0.74-24.74]	R

Permethrin	100	20 [4.32- 35.68]	R

Deltamethrin	100	24 [24.54- 63.46]	R

Bendiocarb	100	72 [54.40- 89.60]	R

Natitingou	East-North	DDT	100	12 [− 0.74-24.74]	R

Permethrin	100	24 [7.26- 40.74]	S

Deltamethrin	100	48 [28.42- 67.58]	R

Bendiocarb	100	76 [59.26- 92.74]	R

Houeyiho	South	DDT	100	8 [−2.63 -18.63]	R

Permethrin	100	8 [−2.63 -18.63]	R

Deltamethrin	100	32 [13.71- 50.29]	R

Bendiocarb	100	60 [40.80- 79.20]	R

Cx. SLAB		DDT	100	100	S

Permethrin	100	100	S

Deltamethrin	100	99	S

Bendiocarb	100	99	S


Author	Year	Study location	Patient(male/female)	Age	Antibody source	Dilution	Method	Definition of abnormal β-catenin expression	Hazard ratio source	HR(95% CI)

Qiao et al.	2001	Germany	43(23/20)	61.1(42–83)	Transduction Laboratories	1:100	IHC	Cytoplasma	Calculated	6.26(1.52–25.76)

Watanabe et al.	2003	Japan	23(14/9)	58.1(25–85)	Transduction Laboratories	1:100	IHC	Membranous reduced	Primary article	1.71(0.44–6.69)

Wang et al.	2013	China	36(25/11)	58.5(34–76)	Santa Cruz	1:200	IHC	Positive cell	Primary article	2.10(0.77–5.72)

Arensman et al.	2014	USA	41(NR)	NR	NR	NR	IHC	Cytoplasma or nuclea	Primary article	3.16(1.19–8.40)

Wu et al.	2015	China	58(37/21)	65(21–80)	Santa Cruz	1:100	IHC	Nuclear expression	Calculated	6.89(2.96–16.03)


Variable	n (%) responders*

Risk behaviour (multiple responses allowed), referenced to time and location as below

Unprotected anal intercourse

 Without ejaculation

insertive	48 (11.9)

receptive	26 (6.5)

 With ejaculation

insertive	35 (8.7)

receptive	23 (5.7)

 Condom failure

insertive	21 (5.2)

receptive	14 (3.5)

Unprotected vaginal intercourse

 Without ejaculation	30 (7.5)

 With ejaculation	43 (10.7)

 Condom failure	19 (4.7)

Oral uptake of body fluids (blood, sperm)	75 (18.7)

Other risk behaviour	39 (9.7)

Risk situations

Partners involved in the risk situation (multiple responses allowed)

 Steady partner	79 (19.7)

 Casual partner	100 (24.9)

 Anonymous partner	148 (36.8)

HIV serostatus of involved partners

 Positive serostatus	28 (7.0)

 Negative serostatus	107 (26.6)

 Serostatus unknown	190 (47.3)

Location of risk situation

 Privat location (at home)	172 (42.8)

 Bathhouse/Darkroom	52 (12.9)

 Park/cruising area	19 (4.7)

 Private party	10 (2.5)

 Other location	42 (10.4)

Time of risk situation

 0 – 3 days ago	21 (5.2)

 4 – 14 days ago	30 (7.5)

 15 days – 3 months ago	109 (27.1)

 3 – 6 months ago	93 (23.1)

 > 6 months ago	52 (12.9)


Model type	Volume [mL]

Analytical model	6.51

Model reconstructed from CT imagining	6.65

Model reconstructed from 3D scanning	6.65

Value of the measurement error	0.14


Treatment	Dose	No. of writhing (10 min)

Saline	10 ml/kg	64.80 ± 1.77

Diclofenac sodium	10 mg/kg	10.40 ± 0.98**

Au-EM	10 mg/kg	29.57 ± 2.97**

20 mg/kg	19.89 ± 3.98**


Variable	Level	Number of observations

Lame leg position	1=Right front	2

	2=Right hind	22

	3=Left front	3

	4=Left hind	16

Locomotion score	0=Negative (<2)	10

	1=Positive (≥2)	33

CMT score	0=Negative (<3)	19

	1=Positive (≥3)	24

Body condition score	0=Negative (<3)	12

	1=Positive (≥3)	31


Patient No.	Diagnosis	Reason

1	cerebral hemorrhage	coma, LTMV

2	high paraplegia	LTMV

3	high paraplegia	LTMV

4	HIE	coma, LTMV

5	cerebral hemorrhage	coma, cerebral hernia

6	Guillain-Barre	LTMV

7	cerebral infarction	coma, LTMV

8	severe thoracic wound	sedation, LTMV

9	cerebral hemorrhage	coma, dyspnea

10	pulmonary heart disease	LTMV

11	refractory heart failure	LTMV

12	refractory heart failure	LTMV

13	tetanus	NMBAs, LTMV

14	cerebral infarction	LTMV

15	cardiogenic shock	LTMV

16	cerebral hemorrhage	coma, dyspnea

17	AMI	LTMV

18	high paraplegia	LTMV

19	HIE	coma, LTMV

20	cerebral infarction	LTMV

21	tetanus	NMBAs, LTMV

22	cerebral hemorrhage	coma, dyspnea

23	cardiogenic shock	LTMV

24	pulmonary heart disease	LTMV

25	HIE	coma, LTMV

26	HIE	sedation, LTMV

27	cerebral hemorrhage	glossocoma, coma, LTMV

28	Guillain-Barre	LTMV

29	severe thoracic wound	sedation, LTMV

30	refractory heart failure	LTMV

31	cerebral infarction	glossocoma, LTMV

32	severe thoracic wound	sedation, LTMV

33	traumatic brain injury	sedation, LTMV

34	cerebral hemorrhage	coma, dyspnea

35	high paraplegia	LTMV

36	respiratory failure	LTMV

37	tetanus	NMBAs, LTMV

38	cerebral infarction	LTMV


Number	Frequency (Hz)	Amplitude (mm)	Measuring Distance (m)	Operating Mode

V-1	8	±4	1.0	Sine-wave

V-2	8	±4	2.0	Sine-wave

V-3	8	±4	3.0	Sine-wave

V-4	8	±4	4.0	Sine-wave

V-5	8	±4	5.0	Sine-wave

V-6	8	±4	6.0	Sine-wave

V-7	8	±4	7.0	Sine-wave

V-8	8	±4	8.0	Sine-wave

V-9	8	±4	9.0	Sine-wave

V-10	8	±4	10.0	Sine-wave

V-11	8	±4	11.0	Sine-wave

V-12	8	±4	12.0	Sine-wave


Slow waves

	Frequency cycles/min	Amplitude mV	Conduction velocity cm/s

	Mean	Range	Mean	Range	Mean	Range

Healthy volunteers	1.6 ± 0.5	1.3–2.1	0.12 ± 0.01	0–0.2	1.6 ± 0.3	1.2–2.1

ED group	1.4 ± 0.3	1.1–1.7	0.15 ± 0.02	0.11–0.21	1.3 ± 0.06	1.1–1.6


Characteristic	Description	N (%)

Gender

	Male	17 (44.7)

	Female	21 (55.3)

Age (years)

	30–39	7 (18.4)

	40–49	6 (15.8)

	50–59	16 (42.1)

	60–69	7 (18.4)

	70 and over	2 (5.3)

Employment

	Employed	35 (92.1)

	Unemployeda	3 (7.9)

Education

	Higher education	19 (50.0)

	Secondary education	12 (31.6)

	Other qualification	4 (10.5)

	None	3 (7.9)

Area of residence

	Notional intervention area	19 (50.0)

	Notional control area	19 (50.0)

Recruitment group

	Intercept	15 (39.5)

	Cohort	23 (60.5)

Behaviour change

	None	11 (28.9)

	More active (away from car)	13 (34.2)

	Less active (towards car)	10 (26.3)

	Change which does not affect activity levels	4 (10.5)

Interviewed previously

	Yes	3 (7.9)

	No	35 (92.1)

Total		38


COMPASS-31 domains	Expanded Disability Status Scale

Correlation coefficient (ρ)	P

orthostatic intolerance	0.079	0.303

vasomotor	0.073	0.341

secretomotor	0.179	0.019

gastrointestinal	0.333	<0.001

bladder	0.563	<0.001

pupillomotor	0.095	0.214

Total score	0.266	<0.001


Response Variable	Comparison	Test	Litters 1–5 (n = 45)	Litters 1–4 (n = 35)

Survival	Across P and 3 dosages of T	Chi-Square	0.0327	0.1362

Survival	P versus pooled T	Chi-Square	0.0039	0.0210

Survival curve (survival over time)	P versus pooled T	Kaplan-Meier	0.0165	0.0658

Weight change	P versus pooled T	t test	0.0014	0.0038

Weight change/h	P versus pooled T	t test	0.0073	0.0132

Brain lesions and neurological signs	Relationship 	Fisher’s exact test	<0.0001	<0.0001

Brain lesions and death	Relationship	Fisher’s exact test	<0.0001	<0.0001

Total brain lesion score	S versus D	t test	<0.0001	<0.0001

Total brain lesion score	P versus T	t test	0.0010	0.0440

% Efficacy against death †	P versus T	1-Relative Risk	<0.0004	<0.001

% Efficacy against brain lesions ‡	P versus T	1-Relative Risk	<0.0004	<0.0086


Demographics	N	%

Gender

 Female	362	59.9

 Male	209	34.6

 not reported	33	5.5

Racial/Ethnic Group

 Asian/Hawaiian/Pacific Islander	9	1.5

 Black	17	2.8

 Hispanic	13	2.2

 White	523	86.6

 Other	9	1.5

 not reported	33	5.5

University Affiliation

 Student	401	66.4

 Faculty	65	10.8

 Staff	90	14.9

 Both student & staff/faculty	24	4.0

 Neither Student nor staff/faculty	24	4.0

Pre-test ST Stage

 Precontemplation	478	79.1

 Contemplation	126	20.9

Access to Car

 I own my own vehicle	535	88.6

 I share a Vehicle	27	4.5

 Neither own nor share	40	6.6

 not reported	2	0.3

Own a Bicycle

 Yes	119	19.7

 No	443	73.3

 not reported	42	7.0

	Mean	SD

Age	28.3	13.9


Diagnosis	N° of cases	N° of images

Melanoma	94	288

Atypical nevi	1785	2677

Benign nevi	18160	21155

Congenital nevi	189	331

Blue nevi	60	105

Combined nevi	18	21

Ungueal nevi	5	7

Lentigo	45	53

Melanosis	80	107

Basal cell carcinomas	55	60

Total	20491	24804


Chinese name	Full scientific name	Parts of plant use	Dose of dry plant (grams)	Dose after extraction (grams)

Xian Ling Pi	Epimedium brevicornum Maxim	Overground part	30	1.5

Tu Si Zi	Cuscuta chinensis Lam.	Mature seed	10	0.5

Du Zhong	Eucommia ulmoides Oliver	Plant bark	15	0.75

Huai Niu Xi	Achyranthes bidentata Bl.	Root	15	6

Ye Xia Zhu	Phyllanthus urinaria Linn.	Whole plant	15	6

Huang Qi	Astragalus membranaceus (Fisch.) Bge.	Root	15	1.5

Bai Shu	Atractylodes macrocephala koidz	Rhizome	15	2.55

Fu Ling	Poria cocos (Schw.) Wolf	Sclerotium	15	1.5

Zhu Ling	Polyporus umbellatus (Pers.) Fries	Sclerotium	10	1.0

Zhi Ke	Fructus Aurantii	Immature fruits (pulp removed)	15	2.55

Dan Shen	Salvia miltiorrhiza Bge.	Root and rhizome	20	3

San Qi	Panax notoginseng (Burk.) F. H. Chen	Root	5	5

Yu Jin	Radix curcumae	Tuberous root	15	0.75

Gou Qi Zi	Lycium barbarum L.	Mature fruit	15	6

Total	 	 	210	38.6


Results	Frequency	Percentage

Sputum with one smear positive	20	50

Sputum with two smear positive	4	10

Sputum with three sputum smear positive	13	32.5

Sputum with smear negative	3	7.5


	2005–2007	2002–2004

Sub-categories	n	%	n	%

chronic hypertension	38	6.1	37	5.9

proteinuric hypertension	173	27.8	171	27.2

eclampsia	344	55.3	347	55.3

HELLP syndrome	54	8.7	70	11.1

rupture of the liver	10	1.6	3	0.5

acute fatty liver	3	0.48	0	0.0

Total	622		628


 	Sampling method

Location	Fluorescent marker	Adenosine triphosphate and microbiologic sampling

Bed rail	Between raised control buttons on the outer surface of the railing closest to room door	Adjacent to fluorescent marker

Overbed tray table	On the upper surface of the table, adjacent to and centered on the edge of the table closest to the hand-operated height adjustment mechanism	Adjacent to fluorescent marker

Call button	On the hand-held device, centered between the emergency button and speaker	Adjacent to fluorescent marker, including raised control buttons

Bedside telephone	Top center of the surface of the receiver, on the obverse side of the earpiece	Adjacent to the fluorescent marker including lateral dial surfaces

Bedside table	Corner closest to the patient bed on the drawer-side (front) top surface [if more than one table is present in the room, the table located to the patient’s right]	Adjacent to fluorescent marker

Chair	On the surface of the seat, in the rear corner closest to the patient bed [if more than one chair present in the room, the chair located closest to the patient bed]	Adjacent to fluorescent marker

Room sink	Corner of the surface adjacent to the basin, closest to the wall and room door	Adjacent to fluorescent marker

Room light switch	Upper left corner of the wall plate	Surface of the light switch plate, over a 2×2-inch surface around but not touching the switch itself

Room door knob, inner	Upper middle of the door plate behind the handle	Surface of the door plate, over a 2×2-inch surface around but not touching the handle

Bathroom light switch	Upper left corner of the wall plate [if electrical sockets are present in upper left, then the upper right corner]	Surface of the light switch pad, over a 2×2-inch surface around but not touching the switch itself

Bathroom hand rail (adjacent to toilet)	Lateral surface of the portion of the handrail farthest from the toilet	Adjacent to the fluorescent mark, with a circumferential sampling of a 2-inch length of railing

Bathroom sink	Corner of the surface adjacent to the basin, to the left and rear of the sink surface	Adjacent to fluorescent marker

Toilet seat	Rear left corner of the seat on the upper surface	Adjacent to fluorescent marker

Toilet flush handle	Superior surface of the handle closest to the plumbing connection	Adjacent to the fluorescent marker, with a circumferential sampling of 1/2 of the handle length

Bedpan cleaner	Surface of the cleaning mechanism behind the spray head (excluding the handle)	Adjacent to fluorescent marker, sampling all surfaces of a lateral half of the cleaning mechanism for a 2-inch length


 	Responders	Non-responders

Gender	13 female, 24 male	4 female, 14 male

Race	50 caucasian, 11 AA	23 caucasian, 8 AA

Log-viral load	14 ± 3.7	15.6 ± 1.6

Metavir	1.6 ± 1.7	1.7 ± 2.3


Primers	Sequence	Enzyme

FLT3-ITD	GCAATTTAGGTATGAAAGCCAGC	-

 	CTTTCAGCATTTTGACGGCAACC

FLT3-TKD	CCGCCAGGAACGTGCTTG	EcoRV

 	GCAGCCTCACATTGCCCC


Variables	TUBA1C-Low	TUBA1C-High	pvalue

Reccurence			0.031

 No	18	11

 Yes	2	8

differentiate			0.103

 1-2	9	3

 3-4	20	25

Primary Tumor stage			0.056

 1-2	26	19

 3-4	3	9

Membrane			0.171

 No	19	11

 Yes	6	8

daughter_nodule			0.079

 No	27	21

 Yes	2	7

embolus			0.029

 No	26	18

 Yes	3	10

AFP			0.014

 Low(<20)	16	7

 High(>20)	11	22


 	Measurement at:	 	Measurement at:

Hemodynamics	 	Acid Base Balance

Noradrenalin requirement (mg/h)	BL – T120	Anion Gap (mmol/L)	BL – T120

Heart rate (min-1)	BL – T120	HCO3- (mmol/L)	BL – T120

ABP systolic (mmHg)	BL – T120	BE (mmol/L)	BL – T120

ABP diastolic (mmHg)	BL – T120	pH	BL – T120

Central venous pressure (mmHg)	BL – T120	paCO2 (mmHg)	BL – T120

Blood loss (mL)	BL – T120

Hemoglobin (g/dL)	BL – T120	Stewart Acid Base Approach [A-] (mmol/L)	BL – T120

Hematocrit (%)	BL – T120	Effective Strong Ion Difference (mmol/L)	BL – T120

Urine quantity (mL)	BL – T120	Strong Ion Gap (mmol/L)	BL – T120

Administered amount of RL/ABIS (mL)	BL – T120	[Albumin] (g/L)	BL – T120

 	 	[Serum-Lactate] (mmol/L)	BL – T120

Serum-Electrolytes([Na+][Cl-] [K+] [Mg++] [Ca++])	BL – T120	[A-]: = Serum-concentration of week acids	BL – T120


Parameter	AT BASELINE	AT 24-WeeksPost E-Cigarette	p value‡

Sustained 50% (excluding quitters) reduction in cigarette smoking (n = 13)

Age	40.1 (± 7.7)†	6 (5, 6)*	< 0.001

Sex	8M; 5F	8 (6, 11)*	0.001

Smoking Years	24.5 (± 8.7)†

Cigarettes/day	25 (20, 30)*

eCO	18 (14, 33)*

Sustained 80% (excluding quitters) reduction in cigarette smoking (n = 5)

Age	40.6 (± 10.4)†	3 (3, 6)*	0.043

Sex	4M; 1F	6 (4, 10)*	0.042

Smoking Years	25.4 (± 11.8)†

Cigarettes/day	30(25, 35)*

eCO	15 (14, 44)*

Sustained 100% (quitters) reduction in cigarette smoking (n = 9)

Age	44.7 (± 9.3)†	0 (0, 0)*	0.008

Sex	8M; 1F	3 (2, 3)*	0.008

Smoking Years	29 (± 9.6)†

Cigarettes/day	25 (23, 30)*

eCO	31 (23, 41)*

Sustained > 50% (including quitters) reduction in cigarette smoking (n = 22)

Age	42 (± 8.5)†	3 (0, 6)*	< 0.001

Sex	16M; 6F	5.5 (3, 9.5)*	< 0.001

Smoking Years	26.3 (± 9.1)†

Cigarettes/day	25 (20, 30)*

eCO	27 (15.5, 37.5)*

Smoking Failure (< 50% smoking reduction) (n = 5)

Age	45.6 (± 7.9)†	20 (20, 20)*	0.157

Sex	2M; 3F	28 (17, 31)*	0.892

Smoking Years	31.2 (± 7)†

Cigarettes/day	25 (20, 25)*

eCO	18 (16, 32)*


Risk factors for invasive candidiasis	Unadjusted odds ratio	95% Confidence interval

Malignancy	3.22	1.36-7.6

Presence of a central venous catheter	13.4	4.8-37.42

Presence of a arterial catheter	1.77	1.02-3.06

Receipt of total parenteral nutrition	5.3	2.8-10.05

Neutropenia within 15 days	5.58	1.12-27.79

Non-candidal blood stream infection within 15 days	2.47	1.35-4.52

Receipt of antifungal agents within 15 days	2.86	1.44-5.66

Receipt of antibiotics within 15 days	5.44	1.87-15.77

Parenteral or oral vancomycin during 1-3 days	2.56	1.27-5.16

Parenteral or oral vancomycin ≥4 days	3.17	1.73-5.82

Extended-spectrum cephalosporins ≥4 days	2.31	1.26-4.22

Carbapenems ≥4 days	3.29	1.1-9.89

Aminoglycosides	2.09	1.17-3.74

Agents covering anaerobic organisms ≥4 daysa	2.3	1.29-4.11


	SPPC (n = 39)	Conventional (n = 38)	p-value

LFC, mean (SD)	85° (4)	84° (3)	0.1

LFC, range	74–94° 	79–89°

LFC, number of outliers > 3°	16/39	33/38	< 0.001

LFC, ICC	0.99	0.99

LTC, mean (SD)	94° (4)	87° (3) 	< 0.001

LTC, range	87–102°	75–92°

LTC, number of outliers > 3°	14	21	0.02

LTC, ICC	0.99	0.99


	OCA2 c.808-3C>G	OCA2 c.2080-2A>G

Wild type score	5.2	11.5

Mutant score	-5.3	0.6


Dataset	Dissimilarity	Linkage	Data permutation method

Simulated6	Euclidean	complete	Independently for each coordinate (column)

(1 - Pearson correlation)	average

Leukemia	Euclidean	Ward	Independently for each gene (column)

(1 - Pearson correlation)	average

T10	Euclidean	Ward	Independently for each chromosome; identically for all cores (columns) in a chromosome

(1 - Pearson correlation)	average

Organelles	(1 - Pearson correlation)	Ward	Independently for each protein (column)

(1 - Pearson correlation)	average

Chondrosarcoma	(1 - Spearman correlation)	Ward	Independently for each surface marker (column)

(1 - Kendall correlation)	average

	Manhattan	Ward


Predictor	P-value	Sub-hazard Ratio	95% CI

EHD >1 site / 1 site outside the lung	0.001	3.0	1.6 - 5.9

Kras mutant	0.009	2.0	1.2 - 3.3

CEA >30 ng/ml	0.056	1.9	0.98 - 3.7


ID	Short description	T	AP	AS	AR

X1	partOfSpeech(token)	✓		✓

X2	syntCat(token)	✓		✓

X3	partOfSpeech(L3)	✓		✓

X4	syntCat(L3)	✓		✓

X5	syntCatPathFromRoot(token)	✓

X6	syntCatCollapsedPathFromRoot(token)	✓

X7	syntCatPositionPathFromRoot(token)	✓

X8	ancestor (token,[1..3])	✓

X9	lowestCommonAncestor (token,neighbourOf (token,left,1))	✓

X10	distanceBetween(token, X9)	✓

X11	posString (trigger)		✓		✓

X12	syntCatString (trigger)		✓		✓

X13	posStringDupl (trigger)		✓		✓

X14	syntCatStringDupl (sent)		✓		✓

X15	containsMainVerb(trigger)		✓		✓

X16	mainVerb(sent)			✓

X17	voiceOfVerb(trigger)				✓


SITE	Baseline assessment	Training	Post-test assessment	8 week follow-up assessment	All 4 steps

N	N	n	n (%)	n

MKT	15	26	22	14/22 (63.6%)	5

MLA	20	26	21	20/21 (95.2%)	10

WPA	14	19	16	13/16 (81.3%)	9

ALL SITES	49	71	59	47/59 (79.7%)	24


	Forward	Reverse

G6Pase	ATGACTTTGGGATCCAGTCG	TGGAACCAGATGGGAAAGAG

PEPCK	CTGGCACCTCAGTGAAGACA	TCGATGCCTTCCCAGTAAAC

LGP	CCAGAGTGCTCTACCCCAAT	CCACAAAGTACTCCTGTTTCAGC

GS	GACACTGAGCAGGGCTTTT	GGGCCTGGGATACTTAAAGC

CPT1α	ACCCTGAGGCATCTATTGACAG	ATGACATACTCCCACAGATGGC

MCAD	GGCAAATGCCTGTGATTCTT	CCATTGCGATCTTGAAACCT

GK	TCCCTGTAAGGCACGAAGACAT	ATTGCCACCACATCCATCTCA

CS	TGCCCACACAAGCCATTTG	CTGACACGTCTTTGCCAACTT

SIRT4	CGCTGCTCAAGATCCCTAAG	GCGACACAGCTACTCCATCA

SIRT6	GGCTACGTGGATGAGGTGAT	GGCTCAGCCTTGAGTGCTAC

GLUT2	CTGCTCTTCTGTCCAGAAAGC	TGGTGACATCCTCAGTTCCTC

GLUT4	TCGTCATTGGCATTCTGGTTG	AGCTCGTTCTACTAAGAGCAC


miRNA name	Reference genome	Location	Annotation	Strand	Mature sequence

HPV16-miR-H1	NC_001526.2	2635–2716	E1	+	AGUGUAUGAGCUUAAUGAUAA

HPV16-miR-H2	FJ610147.1	56-1/7906–7851	LCR	−	AUGUGUAACCCAAAACGGUUUG

HPV16-miR-H3	NC_001526.2	518–642	LCR	+	CAACUGAUCUCUACUGUUA

HPV16-miR-H5	NC_001526.2	2471–2556	E1	+	GUAAAGCAUAGACCAUUG

HPV16-miR-H6	NC_001526.2	6684–6584	L1	–	AUCAACAACAGUAACAAA


ID	Observation	Year	Quarter	Employment	Tenure	Age	FirmID	MassLayoff	Included IntoOur Sample	Pregnancy

1	1	1981	1	Other	––	24	––	––	Not included	No

1	2	1981	2	Work	0.25	24	12	No	Not included	No

1	3	1981	3	Work	0.50	24	12	No	Not included	No

1	4	1981	4	Work	0.75	24	12	No	Not included	No

1	5	1982	1	Work	1.00	25	12	No	Not included	No

1	6	1982	2	Work	1.25	25	12	No	Not included	No

1	7	1982	3	Work	1.50	25	12	No	Not included	No

1	8	1982	4	Work	1.75	25	12	No	Control	No

1	9	1983	1	Work	2.00	26	12	No	Control	No

1	10	1983	2	Work	2.25	26	12	No	Control	No

1	11	1983	3	Work	2.50	26	12	Yes	Control	No

1	12	1983	4	Work	2.75	26	12	Yes	Control	No

1	13	1984	1	Work	3.00	27	12	Yes	Treated	No

1	14	1984	2	Other	––	27	––	Yes	Not included	No

1	15	1984	3	Other	––	27	––	––	Not included	No

1	16	1984	4	Other	––	27	––	––	Not included	No

1	17	1985	1	Other	––	28	––	––	Not included	Yes


Group	Material	Code	Manufacturer	Shade	Organic Matrix	Filler	Filler Loading	LOT Number

Bulk-fill composite	SureFil SDR Flow	SDR	Dentsply Caulk, Milford, DE, USA	U	Modified UDMA, EBPADMA, TEGDMA	Ba-Al-F-B silicate glass, Sr-Al-F silicate glass	68 wt %	1202174

x-tra base	XB	Voco, Cuxhaven, Germany	U	UDMA, BisEMA	no information	75 wt %	1305261

Filtek Bulk Fill	FBF	3M ESPE, St Paul, MN, USA	U	BisGMA, UDMA, BisEMA(6), TEGDMA, substituated dimethacrylate, Procrylat resin	silane treated zirconia/silica, ytterbium trifluoride	64.5 wt %	N414680

Conventional flowable composite	Filtek Ultimate Flow	FUF	3M ESPE, St Paul, MN, USA	A2	BisGMA, TEGDMA, substituated dimethacrylate, Procrylat resin	silane treated zirconia/silica, ytterbium trifluoride	65 wt %	N652740


Diagnostic test	Number (%)

Any laboratory test	73 (22.5)

Urinalysis	71 (21.9)

Bloodwork	30 (9.2)

Any Imaging	96 (29.5)

Plain radiograph	89 (27.4)

CT	15 (4.6)

MRI	2 (0.6)

Plain radiograph and CT	11 (3.4)

CT and MRI	1 (0.3)

Only MRI	1 (0.3)


	NS1-2 gene counts	NS1-2 dis gene counts	NS1-2 aadjusted p-values	NS1-2 disaadjusted p-values

Upregulated gene pathways

 Proteasome	25	15	1.80E−15	2.30E−06

 Aminoacyl-tRNA biosynthesis	14	9	4.80E−05	2.30E−02

 Focal adhesion	27	22	6.90E−03	2.60E−02

 RIG-I-like receptor signaling	14	10	5.60E−03	6.20E−02

 Toll-like receptor signaling	16	13	2.10E−02	5.30E−02

 Pathways in cancer	33	28	7.80E−02	4.80E−02

 NOD-like receptor signaling	11	8	7.20E−02	1.90E−01

 Apoptosis	12	11	1.90E−01	9.50E−02

 Regulation of actin cytoskeleton	22	16	1.80E−01	3.80E−01

 Antigen processing and presentation	11	9	3.00E−01	3.50E−01

 MAPK signaling	24	22	3.00E−01	1.50E−01

 Gap junction	10	10	3.60E−01	1.90E−01

 VEGF signaling	9	9	3.80E−01	1.90E−01

 Cytokine-cytokine receptor interaction	-	20	-	1.80E−01

Downregulated gene pathways

 Lysosome	28	17	1.50E−11	4.30E−05

 Leukocyte transendothelial migration	13	8	2.00E−01	6.30E−01

 Phosphatidylinositol signaling system	9	9	3.30E−01	1.00E−01

 Toll-like receptor signaling	10	7	3.70E−01	5.80E−01

 Regulation of actin cytoskeleton	16	12	4.30E−01	7.30E−01

 Glycosaminoglycan degradation	4	4	6.60E−01	7.50E−01

 Cell adhesion molecules	11	-	7.10E−01	-

 p53 signaling	-	6	-	8.50E−01

 Cytokine-cytokine receptor interaction	-	13	-	6.80E−01

 Focal adhesion	-	11	-	5.90E−01

 mTOR signaling	-	5	-	5.40E−01


 	Patients with a NRAS negative FN (N = 90)	Patients with a NRAS positive FN (N = 33)	P-value

Average FN size (cm)	2.2 ± 1.5	1.4 ± 0.8	<0.001

Age

 ≤45 years	31 (65%)	17 (35%)	0.086

 >45 years	59 (79%)	16 (21%)

Gender

 Female	71 (74%)	25 (26%)	0.710

 Male	19 (70%)	8 (30%)

Final results of FNs

 Benign	52 (83%)	11 (17%)	0.016

 Malignancy	38 (63%)	22 (37%)

Final results of coexisting nodules∗

 Benign	26 (83%)	10 (28%)	0.080

 Malignancy	12 (63%)	12 (50%)

Total risk of malignancy	53% (47/90)	79% (26/33)	0.008


Predicted syndromes	 Recorded syndromes

Qi deficiency of spleen and kidney (n = 80)	Deficiency of both qi and yin (n = 14)

Qi deficiency of spleen and kidney	70 (87.5)	13 (92.9)

Deficiency of both qi and yin	4 (5.0)	1 (7.1)

Other types	6 (7.5)	0


Type of publication	Average citation per paper

All papers	12.2

Case reports	6.24

Comparative studies	16.9

Reviews	10.89

Multicenter	23.94

RCT#	25.57

Evaluation	9.92

Top ten	22.75

Collaboration between 2 AL countries	11.2

Collaboration between 3 AL countries	19.2


	Date	Test	Results

Case 1	Apr. 17, 2013	NMDAR antibodies	Serum: positive (+)

CSF: Strong positive (++)

Apr. 18, 2013	Pelvic CT	Left ovarian cystic lesions

Apr. 22, 2013	Pelvic Ultrasound	Left ovarian cyst

May 9, 2013	NMDAR antibodies	Serum: Weakly positive

CSF: positive (+)

May 14, 2013	Anatomopathology	Ovarian mature cystic teratoma

May 22, 2013	NMDAR antibodies	Serum: Negative (−)

CSF: Weakly positive

Case 2	June 16, 2014	NMDAR antibodies	Serum: positive (+)

June 23, 2014	NMDAR antibodies	Serum: Weakly positive

CSF: positive (+)

June 26, 2014	Pelvic Ultrasound	Right ovarian cyst

June 26, 2014	Pelvic MRI	Right ovarian cystic lesions

July 1, 2014	Anatomopathology	Ovarian mature cystic teratoma

July 7, 2014	NMDAR antibodies	Serum: Negative (−)

CSF: positive (+)


	N = 1129 Lesions in 964 Subjects

Navigation Success (per lesion)a	91.8% (1036/1129)

Navigation Success (per subject)a	94.4% (910/964)

Number of Lesions Biopsied (per subject)	1.2 ± 0.5 (964) [1.0] (1.0–5.0)

Biopsy Tools Used During ENB Index Procedureb

 Aspiration Needle	52.2% (503/964)

 Biopsy Forceps	81.2% (783/964)

 Cytology Brush	47.0% (453/964)

 Needle-Tipped Cytology Brush	20.2% (195/964)

 Triple Needle-Tipped Cytology Brush	23.4% (226/964)

 GenCutTM Core Biopsy Tool	18.9% (182/964)

 Bronchoalveolar Lavage or Washing	37.8% (364/964)

Rapid on-site evaluation (ROSE) usedc	66.1% (601/909)

Molecular/genetic testing attemptedd	28.3% (70/247)

 Molecular/genetic testing successful	80.0% (56/70)

 Inadequate Sample	20.0% (14/70)

Molecular/genetic testing not attemptedd	71.7% (177/247)

 Not Necessary	49.2% (87/177)

 Not Standard Practice	41.2% (73/177)

 Other	9.6% (17/177)


Bacteria	Antibiotics (100 mg ml-1)	Larval Extracts (200 mg ml-1)

L. cuprina	S. peregrina	M. domestica

S. aureus	Chloramphenicol 1.56	100.0	-	-

MRSA	Chloramphenicol 25.0	100.0	100.0	100.0

P. aeruginosa	Gentamicin 1.56	100.0	-	-

E. coli	Gentamicin 0.78	100.0	-	-


Infection parameters	Distributions

 	Gonorrhoea	Reference	Chlamydia	Reference

Probability of infection being symptomatic

Male	β (0.9, 0.05)	[12-15]	β (0.30, 0.15)	[12,13]

Female	β (0.4, 0.15)	[12-15]	β (0.15, 0.08)	[12,13]

Duration of latent period (days)	U (3, 5)	[13,16-18]	U (12, 28)	[13,17,19]

Duration of asymptomatic infection in the absence of treatment (days)	Γ (105, 35)	[12,13,20]	Γ (220, 188)	[12,19,21-24]*

Duration of symptomatic infection in the absence of treatment (days)	Γ (105, 35)	[12,13,20]	Γ (112, 35)	[12,25]

Duration of immunity following recovery (days)	Γ (7, 3.5)	-	Γ (45, 15)	-

Transmission probability per sex act

Male to Female	β (0.2, 0.05)	[12,21,26,27]	β (0.16, 0.10)	[12,19,28,29]

Female to Male	β (0.4, 0.10)	[12,21,26,30,31]	β (0.12, 0.06)	[12,19,28,29]


 Evaluated parameters	 	DF group (n = 104)*	C group (n = 48)**	P value

Education level	Basic education/training (% of patients)	30.4	8.4	P < 0.001

Secondary without leaving exam (% of patients)	25.5	16.7	NS

Secondary with leaving exam (% of patients)	30.4	33.3	NS

University (% of patients)	13.7	41.7	P < 0.001

Employment status	Full-time job (% of patients)	11.7	29.2	P < 0.001†

Part-time job (% of patients)	4.9	2.1	NS

Business (% of patients)	4.9	18.8	P < 0.001†

Old age pension (% of patients)	34	39.6	NS

Disability pension (% of patients)	41.7	6.2	P < 0.001†

Others (% of patients)	2.9	4.2	NS

Self-support	Fully self-support (% of patients)	38.1	87.2	P < 0.001††

Partially self-support (% of patients)	55.7	12.8	P < 0.001††

Fully dependent on the assistance of other persons (% of patients)	6.2	0	NS


Group	Number of subjects	M/F	Age

Low SES	25	14/11	24.4 ± 1.2

Mid SES	27	14/13	23.1 ± 1.2


Proposal ingredient	Key question	Review criteria	Check (yes/no)

1. The care gap or quality gap	The proposal has clear evidence that a gap in quality exists?	Significance Impact

2. The evidence-based treatment to be implemented	Is the evidence for the program, treatment, or set of services to be implemented demonstrated?	Significance Innovation

3. Conceptual model and theoretical justification	The proposal delineates a clear conceptual framework/theory/model that informs the design and variables being tested?	Approach Innovation

4. Stakeholder priorities, engagement in change	Is there a clear engagement process of the stakeholders in place?	Significance Impact Approach Environment

5. Setting’s readiness to adopt new services/treatments/programs	Is there clear information that reflects the setting’s readiness, capacity, or appetite for change, specifically around adoption of the proposed evidence-based treatment?	Impact Approach Environment

6. Implementation strategy/process	Are the strategies to implement the intervention clearly defined, and justified conceptually?	Significance Impact Innovation

7. Team experience with the setting, treatment, implementation process	Does the proposal detail the team’s experience with the study setting, the treatment whose implementation is being studied, and implementation processes?	Approach Investigator team

8. Feasibility of proposed research design and methods	Does the methods section contain as much detail as possible, as well as lay out possible choice junctures and contingencies, should methods not work as planned?	Approach Investigator team

9. Measurement and analysis section	Does the proposal clarify the key constructs to be measured, corresponding to the overarching conceptual model or theory?	Approach Investigator team

Is a measurement plan clear for each construct?

Does the analysis section demonstrate how relationships between constructs will be tested?

10. Policy/funding environment; leverage or support for sustaining change	Does the proposal address how the implementation initiative aligns with policy trends?	Impact Significance


	WCST Error Score

	Component 1	Component 2

	(7.4% Variance)	(6.5% Variance)

Age	0.391

Education	−0.538

Income	−0.295

Proficiency L1	−0.283

Open to experiences	−0.258

QoL		0.437

Attitude L3		0.436

Emotional stability		0.280


GO biological process terms	p-value	GO biological process terms	p-value

Genes up-regulated in erythroblasts

heme biosynthesis	8.3593E-09	tRNA metabolism	4.7686E-04

heme metabolism	4.1178E-08	nitrogen compound metabolism	0.0011

pigment biosynthesis	7.8243E-08	cholesterol biosynthesis	0.0021

porphyrin biosynthesis	8.0158E-08	amino acid activation	0.0022

pigment metabolism	1.8805E-07	tRNA aminoacylation for protein translation	0.0022

porphyrin metabolism	2.5313E-07	tRNA aminoacylation	0.0022

carboxylic acid metabolism	3.5431E-07	electron transport	0.0023

organic acid metabolism	4.0819E-07	amino acid and derivative metabolism	0.0025

secondary metabolism	5.8601E-07	amine metabolism	0.0037

heterocycle metabolism	4.7133E-06	lipid metabolism	0.0037

cellular biosynthesis	6.9372E-06	steroid biosynthesis	0.0041

cofactor metabolism	1.0534E-05	cholesterol metabolism	0.0041

cofactor biosynthesis	1.9914E-05	iron ion homeostasis	0.0042

generation of precursor metabolites and energy	3.9831E-05	sterol biosynthesis	0.0045

cellular metabolism	5.6290E-05	mitotic cell cycle	0.0059

lipid biosynthesis	1.6546E-04	alcohol metabolism	0.0060

cellular lipid metabolism	2.3765E-04	sterol metabolism	0.0061

amino acid metabolism	4.3568E-04

Genes up-regulated in megakaryoblasts

hemostasis	0.0010	positive regulation of cell proliferation	0.0024

endocytosis	0.0011	steroid metabolism	0.0024

cellular lipid metabolism	0.0012	lipid biosynthesis	0.0026

wound healing	0.0014	regulation of receptor mediated endocytosis	0.0034

lipid metabolism	0.0020	localization of cell	0.0049

alcohol metabolism	0.0020	cell motility	0.0049

regulation of body fluids	0.0024	cytoskeleton organization and biogenesis	0.0081

transport	0.0024	cholesterol biosynthesis	0.0089

Genes up-regulated in monoblasts

response to biotic stimulus	6.3071E-15	antimicrobial humoral response	3.1669E-04

immune response	2.8466E-13	detection of stimulus	6.8750E-04

defense response	7.3698E-13	protein kinase cascade	0.0010

response to pest, pathogen or parasite	1.2074E-12	wound healing	0.0014

response to other organism	2.4524E-12	intracellular signaling cascade	0.0017

response to external stimulus	1.0443E-10	positive regulation of cellular process	0.0017

response to stimulus	8.1038E-10	endocytosis	0.0019

response to wounding	1.3630E-09	I-kappaB kinase/NF-kappaB cascade	0.0025

response to stress	2.1560E-08	lymphocyte activation	0.0031

inflammatory response	3.0602E-08	blood coagulation	0.0034

cell communication	5.0323E-07	taxis	0.0035

signal transduction	7.7480E-07	chemotaxis	0.0035

organismal physiological process	8.0044E-07	innate immune response	0.0037

response to pathogen	3.1842E-06	coagulation	0.0038

humoral immune response	3.4723E-05	locomotory behavior	0.0044

detection of biotic stimulus	4.6946E-05	hemostasis	0.0045

response to bacteria	6.7200E-05	carbohydrate metabolism	0.0048

response to pathogenic bacteria	9.7266E-05	cell surface receptor linked signal transduction	0.0059

immune cell activation	1.0815E-04	positive regulation of biological process	0.0064

cell activation	1.2116E-04	macrophage activation	0.0093

humoral defense mechanism (sensu Vertebrata)	1.4837E-04	regulation of body fluids	0.0097

antimicrobial humoral response (sensu Vertebrata)	2.8361E-04

Genes up-regulated in myeloblasts

carboxylic acid metabolism	2.2728E-05	defense response	0.0018

organic acid metabolism	2.3815E-05	response to biotic stimulus	0.0025

cellular biosynthesis	7.1605E-04	immune response	0.0048

biosynthesis	0.0016	positive regulation of cell proliferation	0.0069


AGRF ID	GenBank Accession	UniGene Cluster	Gene	Fold Change	P Value

H3084H06	BG070211	Mm.25335	EST: Cdc14b: CDC14 cell division cycle 14 homolog B (S. cerevisiae)	+ 3.1	0.044

H3137G08	BG074662	Mm.197274	EST: Moderately similar to GNMSLL retrovirus-related reverse transcriptase homolog – mouse retrotransposon (M. musculus)	+ 3.0	0.046

H3123E03	BG073512	Mm.197252	EST: Weakly similar to TLM MOUSE TLM PROTEIN (M. musculus)	+ 2.9	0.047

H3073G12	BG069200	Mm.328026	EST: Transcribed sequence with moderate similarity to protein ref:NP_083358.1 (M. musculus); RIKEN cDNA 5830411J07	+ 2.5	0.038

H3082G05	AU014577	Not assigned	EST	+ 2.1	0.032


	Mean (SD)

Age	43.7 (9.9) years

Gender	11 males, 12 females

Center-edge angle	33.7 (7.8)°

Alpha angle	73 (9.6)° (all alpha angles were 55° or greater)

Loose bodies visible on radiographs	5 (23.8%)

Loose bodies visible on MRI	14 (66.6%)

Tonnis grade	Grade 0 in 14 patients (66.6%)

Grade 1 in 7 patients (28.5%)

Grade 2 in one (4%)


Period	Activity	Who involved

Month 1	Consultation and sensitisation of Kilifi District stakeholders	1. MoH structure: District Medical Officer of Health and District Health Management Team at Kilifi District Hospital. All health facility in-charges working in Kilifi District

2. Provincial administration structures: District Commissioner, Senior District Officer, all chiefs working in Kilifi District

Months 2 to 6	Community entry and sensitisation of stakeholders in sites A, B and C respectively	1. MoH Structure: Dispensary health committees, dispensary staff (facility in-charges, nurses, public health officers, community health extension workers), and community health workers (CHWs)

2. Local administration: District officers, local (assistant) chiefs and village elders

3. Others: primary school head teachers, religious leaders, a local District Stakeholders Forum

Months 8 to 13	Identification and recruitment of 5 to 17 month-old children (n = 600)	CHWs and fieldworkers

Months 15 to 27	Identification and recruitment of 6 to 12 week-old children (n = 304)	CHWs and fieldworkers

From month 8 to date	Follow-up of research participants	Fieldworkers

Continuous feedback to and from community	Fieldworkers and other key gatekeepers

Feedback of results	Involves all of the above, for example, preliminary study results disseminated


Academic year	Number of students	Verbally noted by student during simulation* N(%)	Written in note after simulation N(%)

Student discovered that acetaminophen was administered n(%)	Student established the dosage of acetaminophen	Student stated that the dose was too high	Student identified medication error in write up	Male	Female

2010-11	114	88 (77)	44 (39)	12 (11)	12 (11)	4 (4)	8 (7)

2011-12	108	44 (41)	49 (45)	9 (8)	9 (8)	8 (7)	1 (1)

2012-13	118	102 (86)	68 (58)	16 (14)	13 (11)	7 (6)	6 (5)

Total	340	234 (69)	161 (47)	37 (11)	34 (10)	19 (6)	15 (4)


	Loci	Ref	Var	Gene	Variant type	Novel	Frequency of Mutation

Mismatch Repair

	80149981	A	G	MSH3	nonsynonymous SNV	0	0.60

	80168937	G	A	MSH3	nonsynonymous SNV	0	0.51

	79950724	G	C	MSH3	nonsynonymous SNV	0	0.02

	48023115	T	C	MSH6	synonymous SNV	0	0.14

	48030588	C	T	MSH6	stopgain	0	0.06

Tumor Suppressor

	63410110	T	C	AMER1	synonymous SNV	0	0.08

	63412690	A	C	AMER1	nonsynonymous SNV	0	0.06

	63411276	G	A	AMER1	stopgain	0	0.06

	63411684	G	T	AMER1	nonsynonymous SNV	1	0.06

	112162854	T	C	APC	synonymous SNV	0	0.52

	112164561	G	A	APC	synonymous SNV	0	0.49

	112176325	G	A	APC	synonymous SNV	0	0.49

	112176559	T	G	APC	synonymous SNV	0	0.54

	112177171	G	A	APC	synonymous SNV	0	0.59

	112176756	T	A	APC	nonsynonymous SNV	0	0.57

	112175770	G	A	APC	synonymous SNV	0	0.49

	112164586	C	T	APC	stopgain	0	0.06

	7579472	G	C	TP53	nonsynonymous SNV	0	0.40

	48604664	C	T	SMAD4	nonsynonymous SNV	1	0.08

Oncogenes

	70118935	C	T	SOX9	synonymous SNV	0	0.13

	114912121	G	A	TCF7L2	synonymous SNV	0	0.08

	114910829	A	G	TCF7L2	synonymous SNV	0	0.05

	30732970	G	A	TGFBR2	nonsynonymous SNV	0	0.06

	30713842	C	T	TGFBR2	synonymous SNV	0	0.02

	178916890	C	T	PIK3CA	nonsynonymous SNV	0	0.06

	178952085	A	G	PIK3CA	nonsynonymous SNV	0	0.06

	25368462	C	T	KRAS	synonymous SNV	0	0.67


 	 	P. falciparum ortholog	P. vivax ortholog

Protein description	Ortholog group	PlasmoDB Gene ID	SP prediction	Predicted localization	PlasmoDB Gene ID	SP prediction*

Proline tRNA synthetase	OG4_11662	PFI1240c	+	Apicoplast	PVX_099680 ®	+

 	OG4_10599	PFL0670c	-	Cytosol	PVX_123380	-

Asparagine tRNA synthetase	OG4_44547	PFE0475w	+	Apicoplast	PVX_098040 ®	+

 	OG4_10251	PFB0525w	-	Cytosol	PVX_002940	-

Methionine tRNA synthetase	OG4_47490	PF10_0053	+	Apicoplast	PVX_094445 ®	+

 	OG4_10161	PF10_0340	-	Cytosol	PVX_110980	-

Leucine tRNA synthetase	OG4_11105	PF08_0011	+	Apicoplast	PVX_088945 ®	+

 	OG4_10828	PFF1095w	-	Cytosol	PVX_114255	-

Glutamate tRNA amidotransferase subunit A	OG4_10803	PFD0780w	+	Apicoplast	PVX_089895 ®	+

Initiation Factor-1	OG4_12019	MAL8P1.27	+	Apicoplast	PVX_089095 ®	+

Initiation Factor-3	OG4_14117	PF14_0658	+	Apicoplast	PVX_117015 ®	+

DNA gyrase subunit A	OG4_12828	PFL1120c	+	Apicoplast	PVX_123795 ®	+

 	OG4_10491	PF14_0316	-	Nucleus	PVX_084855	-

DNA gyrase subunit B	OG4_12159	PFL1915w	+	Apicoplast	PVX_100925 ®	+

 	OG4_10746	PF10_0412	-	Nucleus	PVX_111340	-

Ferredoxin	OG4_14702	MAL13P1.95	+	Apicoplast	PVX_122725 ®	+


Number of patients	Total

 	n = 2,270

Age, years (SD)	61.7 (17.0)

Sex, male (%)	1,277 (56.3)

Height, metres (SD)	1.68 (0.11)

Weight, kg (SD)	78.1 (26.0)

BMI, mean (SD)	27.6 (8.3)

BMI, n (%)

<24	1,039 (45.9)

25-29	594 (26.2)

30-40	463 (20.4)

>40	169 (7.5)

Admission type

Medical, n (%)	2,270 (100)

Surgical	0

ICU admission diagnosis, n (%)

Aspiration pneumonia	330 (14.5)

Bacterial/viral pneumonia	911 (40.1)

Sepsis (other than urinary tract)	859 (37.8)

Sepsis of urinary tract origin	170 (7.5)

APACHE II score, mean (SD)	23.9 (7.9)

Days from hospital admission to ICU admission (hours), median [IQR]	6.55 [0.08, 65.08]

Days from hospital admission to ICU admission, n (%)

[0–1] day	1,437 (63.4)

[1-3] days	303 (13.4)

>3 days	527 (23.3)

Length of ICU stay (days), median [IQR]	11.5 [6.9-21.4]

Length of hospital stay (days), median [IQR]	23.8 [13.8-48.5]

Length of mechanical ventilation (days), median [IQR]	8.4 [4.6-19.2]

Ventilator-free days, median [IQR]	46.4 [4.0-55.0]

Mortality (60 day),%	30.5


	Group A (n = 45)	Group B (n = 31)		Group C (n = 18)

	Stool		Duodenal fluid		Stool

	Kato-Katz	Filtration	Kato-Katz	Kato-Katz

Helminth species	Positive/examined (%)	Intensity (epg)	Positive/examined (%)	Intensityb	Positive/examined (%)	Intensity (epg)	Positive/examined (%)	Intensity (epg)

		Median (range)		Median (range)		Median (range)		Median (range)

Opisthorchis viverrini	45/45 (100)	900 (60–13,710)	19/32 (59.4)	24 (1–7140)	15/29 (52.7)	40 (24–56)	9/18 (50.0)	24 (24–40)

Hookworma	18/45 (40.0)	180 (30–2940)	4/32 (12.5)	13 (5–27)	6/29 (20.7)	24 (24–72)	0/18 (0)	n.a.

T. trichiura	4/45 (8.9)	n.d.	0/32 (0)	n.a.	0/29 (0)	n.d.	0/18 (0)	n.a.

Taenia spp.a	7/45 (15.6)	n.d.	0/32 (0)	n.a.	0/29/0)	n.a.	0/18 (0)	n.a.

Trichostrongylus spp.b	0/45 (0)	n.a.	0/32 (0)	n.a.	3/29 (10.3)	n.d.	2/18 (11.1)	n.d.


OPEN APPENDECTOMY	Nr. UNITS	TOTAL

2/0 silk suture	3	0.4 €

2/0 braided absorbable suture	2	4.3 €

Suction device	1	2.3 €

TOTAL	 	7 €

LAPAROSCOPIC APPENDECTOMY

Hasson Trocar	1	37 €

5 mm Trocar	2	70 €

Endoclinch	1	75 €

Lap. Irrigation/suction device	1s	70 €

Biosyn® 3/0	2	4.3 €

1-Ti-Cron® suture	1	3 €

TOTAL	 	259.3 €

DIFFERENTIAL	 	+ 252.3 €


Social variable	Nonpregnant women	Pregnant women

Age (years)	29.250 ± 2.314	28.333 ± 1.971

Ethnicity	Han	Han

Occupation

 Housewife	0	3

 Employee	20	27

Level of education

 <Technical	6	10

 Bachelor	9	13

 Master	5	7

Economic status	Regular	Regular


Diet ingredients, % (DM basis)	Ratio

Corn stalk pellets	60.0

Corn	24.8

Soybean meal	10.4

Wheat bran	3.2

Sodium chloride	0.4

Calcium hydrophosphate	0.8

Premixa	0.4

Nutrient composition (DM basis)

Dry matter, %	93.56

Digestible energy, MJ/kg	8.13

Crude protein, %	10.39

Ether extract, %	8.15

Neutral detergent fiber, %	22.79

Acid detergent fiber, %	16.0

Vitamin E, IU/kg	5.08


Comp-ound	Docking Score	Residue involv-ed in hydrogen bonds	Residues involv-ed in π-π intera-ctions

9	-6.76	Asp-168	Lys 53, Arg 67

10	-6.70	Asp-168	Arg 67

11	-4.30	Asp-168	His 148, Arg 67

12	-5.29	Asp-168	-

13	-4.52	Asp-168	His 174, Arg 67

14	-4.69	Met-109	Phe 169

15	-5.19	Asp-168	Arg 67


	Positive influenza A	Positive influenza B	Negative samples

Seasonal H1N1	2009 pandemic H1N1	H3N2	H5N1

RT-qPCR	14	39	29	2	69	80

Multiplex DPO PCR	13	25	16	2	43	134

Positive Concordant Percentage	56 (66.67%, 56/84)	43(62.32%, 43/69)	____


Wealth variable	Response options	Crude score	Rescaled crude score	Assigned weight	Weighted score

Main roof material	Cement/concrete	4	1.00	5	5.00

Corrugated iron	3	0.67	 	3.35

Wood planks/wood	2	0.33	 	1.65

Thatch / leaf/reed/bamboo	1	0.00	 	0.00

Type of toilet facility	Flush to septic tank/sewer system/pit latrine	6	1.00	4	4.00

Ventilated improved pit latrine (VIP)	5	0.80	 	3.20

Pit latrine with slab	4	0.60	 	2.40

Pit latrine without slab / open pit	3	0.40	 	1.60

Composting toilet	2	0.20	 	0.80

No facility / bush / field	1	0.00	 	0.00

Educational attainment	Higher	6	1.00	3	3.00

Complete secondary	5	0.80	 	2.40

Incomplete secondary	4	0.60	 	1.80

Complete primary	3	0.40	 	1.20

Incomplete primary	2	0.20	 	0.60

No education	1	0.00	 	0.00

Household owns table	Yes	2	1.00	2	2.00

No	1	0.00	 	0.00

Household has radio	Yes	2	1.00	1	1.00

No	1	0.00	 	0.00


Number	Raw CW (g)	Water Added (mL)	Mixing Condition	Final Liquid Volume (mL)	Recovery (g sugars/kg raw CW)

1	250	250	Mixer	170	19.7

2	150	250	Mixer	250	29.7

3	250	250	Shaking at 120 rpm (15 min)	250	24.8

4	150	250	Shaking at 120 rpm (15 min)	250	30.3


Operation	Duration (ms)

Conceptual preparation (from picture onset to selecting the target concept)	175

Lemma retrievalForm encoding:	75

Phonological code retrieval	80

Syllabification	125

Phonetic encoding (till initiation of articulation)	145

Total	600


Excluded species	Reasons for exclusion

Baissopsyche pura	Forewing venation not complete, key characters missing

Mesopsyche ordinata	Forewing width/length ratio at 0.48 much higher than that of all others (with typical ratio between 0.30 and 0.35 and two outliers at 0.27 and 0.38)

Mesopsyche justa	Base of forewing missing for holotype; inconsistent venation among holotype and paratypes.

Mesopsyche gentica	Base of forewing missing

Mesopsyche tortiva	Incomplete forewing and base of hind wing missing

Mesopsyche incompleta	Incomplete fore- and hind wings

Mesopsyche javorskii	Hind wing only

Mesopsyche tongchuanensis	Incomplete forewing only

Mesopanorpodes wianamattensis	Anal area of forewing missing

Permopsyche robustus	Incomplete forewing only

Mesoses optata	Incomplete forewing only

Mesoses magna	Incomplete forewing only

Mesoses gayndah	Incomplete forewing only

Ptychopteropsis mirabilis	Incomplete forewing only

Turanopsyche venosa	Incomplete hind wing only

Ferghanopsyche rotundata	Incomplete forewing only


 	Cryptography authentication	Biometrics recognition

Authentication method	Digital	Analog

Authentication rule	Without error tolerance	With error tolerance

Data processing	Data is disordered	Data is processed but not disordered

Adoption of cryptography technique	Data can be encrypted and signed	Data cannot be encrypted or signed


Case	Removal of catheter	Antifungal treatment	Outcome	References

1	Yes	AmB (cumulative dose, 0.3 g)	Switching to permanent hemodialysis	[18]

2	Yes	AmB (cumulative dose, 2 g)	Cured	[20]

3	Yes	AmB + 5-FC	Died	[20]

4	Yes	AmB (cumulative dose, 1.4 g) + 5-FC (cumulative dose, 55 g)	Switching to permanent hemodialysis	[19]

5	Yes	MCZ × 3 days + AmB (cumulative dose, 0.5 g)	Cured	[16]

6	Yes	KCZ 400 mg/day × 2 days + FCZ 400 mg/day × 5 days	Cured	[21]

7	Yes	AmB 0.5 mg/kg/day × 6 weeks +5-FC × 4 weeks	Switching to permanent hemodialysis	[22]

8	Yes	(FCZ 200 mg/day + CPF 50 mg/day) × 5 days + AmB liposomal 400 mg/day × 7 days	Switching to permanent hemodialysis	[14]

9	Yes	FCZ200 mg/day × 6 days + AmB 0.5 mg/kg/day × 4 weeks	Switching to permanent hemodialysis	[15]

10	Yes	VCZ 500 mg × 8 days	Cured	[13]

11	No	AmB (cumulative dose, 2.5 g) + 5-FC 50 mg/kg × 6 weeks	Cured	[23]

12	No	AmB (cumulative dose, 1.9 g)	Cured	[17]

13	Yes	AmB 0.5 mg/kg/day × 6 weeks	Died	[24]

14	ND	ND	Died	[27]

15	No	(AmB + 5-FC) × 9 days + FCZ × 24 weeks	Cured	[26]

16	No	VCZ 400 mg/d × 10 days + AmB 100 mg/day × 4 days + 	Cured	[25]

17	No	(VCZ 0.4 g/day + 5-FC 4 g/day) × 2 weeks	Cured	This study

18	No	(AmB 30 mg/days + 5-FC 4.5 g/day) × 4 weeks	Cured	This study


CESD-10 score category	n	Total tremor score	ETEA score	Number (%) who had been prescribed medication for tremor

0–9 (no or minimal depressive symptoms)	47	19.6 ± 6.2	19.9 ± 16.4	28 (59.6)

10–19 (moderate depressive symptoms)	37	22.1 ± 5.8	28.4 ± 16.4	24 (64.9)

≥20 (severe depressive symptoms)	7	19.0 ± 2.0	31.4 ± 17.6	7 (100)

		p = 0.36a	p = 0.01b


Groupsa	Immunization time

1st	2nd	3rd	4th

PBS	100 μl	100 μl	100 μl	100 μl

pEGFPb	100 μg	100 μg	100 μg	100 μg

pGRA4c	100 μg	100 μg	100 μg	100 μg

peptided	100 μg	100 μg	100 μg	100 μg

peptide/DNA	100 μg peptide	100 μg peptide	100 μg pGRA4	100 μg pGRA4

DNA/peptide	100 μg pGRA4	100 μg pGRA4	100 μg peptide	100 μg peptide


Variables	 Frequency	 Percent

Number of pregnancies

 1	161	29.7

 2-3	276	50.9

 4+	105	19.4

Gestational age

 ≤16	10	 1.9

 17–24	134	24.7

 25–35	333	61.4

 ≥36	65	12.0

Antenatal visit

 Yes	312	57.6

 No	230	42.4

Number of ANC visit (n = 312)

 1	122	39.1

 2-3	176	56.4

 4+	14	 4.5

Received information from health care providers

 On HIV

Yes	346	63.8

No	196	36.2

 On antenatal care

Yes	304	56.1

No	238	43.9

 On MTCT

Yes	284	52.4

No	258	47.6

 On infant feeding

Yes 	181	33.4

No 	361	66.6

Comprehensive knowledge of HIV/AIDS

 Yes 	346 	63.8

 No	196	36.2

Heard of PITC

 Yes 	345 	63.7

 No	197	36.3

Heard about MTCT

 Yes 	458 	84.5

 No	84	15.5

Know the means of transmission on MTCT (n = 458)

 During pregnancy	309 	67.5

 During labor/delivery	324 	70.7

 During breast feeding	251 	54.8

Exact timing of MTCT answered by women

 None	84	 15.5

 One	130 	24.0

 Two	225 	41.5

 Three	103 	19.0


 	No. of contigs with hits	No. of unique accessions	No. of unique protein hits

Zebrafish RefSeq	87,931	19,711	19,711

Uniprot/Swiss-Prot	80,012	26,396	17,669

Total	94,476	-	25,144


Parameters	Results

Weight (g)	24.9±3.1

Peak CSA [ mm2]

Cartesian Measurement	0.75±0.05

Radial Triggered Measurement	0.75±0.04

Retrospective Measurement	0.73±0.04

Peak volume flow [ cm3/s]

Cartesian Measurement	0.27±0.04

Radial Triggered Measurement	0.28±0.03

Retrospective Measurement	0.28±0.04

PWV [m/s]

Cartesian Measurement	2.4±0.2

Radial Triggered Measurement	2.3±0.2

Retrospective Measurement	2.3±0.2


Chiropractor ID	Number of diagnoses coded	Agreement on *rubric level(%)	Agreement on **term level(%)

1	9	89	67

2	20	15	10

3	12	92	50

4	15	60	0

5	14	29	29

6	9	67	56

7	14	29	7

8	10	100	100

9	16	44	31

10	11	82	73

11	10	100	10

12	11	27	18

13	12	0	0

14	4	75	0

Overall agreement %		52	35

Agreement expected by chance		17	6

Overall agreement (Cohen’s Kappa)	Total number of codes: 167	0.4 (95% CI 0.3-0.7)***	0.3 (95% CI 0.2-0.5)***


Measure	Sample size	Mean score (SD)

Adverse childhood experience (ACE) score	n = 67	1.93 (2.45)

ACE z-score	n = 67	0.053 (0.94)

ACE (range)	n = 67	0.00–10.00


Prevalence (%)	Men	Women	Total

Diabetes	14.0	10.0	11.6

Dyslipidemia	27.4	34.8	31.8

Hypertension	30.2	36.2	33.7

Smoking	12.6	7.9	9.8

Obesity	17.3	21.5	19.8


Demographics	Baseline	Follow-up

Male, n	19 (61%)

Mean age + −SD, years 70.2 (SD 11.7)

< 9 years of education	5 (16%)

Stroke subtype

 Cerebral infarction	29 (94%)

 TIA	2 (6%)

Risk factors, n

 Hypertension	20 (65%)

 Hyperlipideamia	23 (74%)

 Diabetes	6 (19%)

 Current smoking	7 (23%)

 Atrial fibrillation	3 (10%)

 BMI	18 (58%)

TOAST classification, n

 Large-vessel disease	2 (7%)

 Cardio-embolic disease	2 (6%)

 Small vessel disease	17 (55%)

 Stroke of undetermined aetiology	10 (32%)

OCSP classification, n

 TACI	0

 PACI	13 (42%)

 LACI	15 (48%)

 POCI	3 (10%)

Assessments

 NIHSS, day 1, mean (IQR)	3.06 (1.0-4.0)	0.58 (0.0-1.0)

 BI, mean(IQR)	18.5 (19.5-20.0)	19.48 (20.0-20.0)

 mRS, mean (IQR)	1.35 (0.0-3.0)	1.06 (1.0-1.0)

 Total TAU, mean (IQR)		363 (227–382)

 Apoɛ4	9 (29%)

 TMT A (seconds) (SD)	86.0 (±97.0)	61.6 (±48.4)

 MMSE (points) (SD)	26.0 (±3.8)	26.7 (±3.9)

 10 word test (words)	20.1 (±6.8)	24.5 (±6.1)

 Ventricular volume (mm^3)(SD)	60,796 (±17,339)	60,334 (±25,118)

 Global brain volume(mm^3) (SD)	1,404,660 (±63,160)	1,368,194 (±142,856)


Sample	N (mmol/g)	C (mmol/g)	Molar ratio of C/N	CO2 adsorption capacity (mmol/g)	Amine efficiency

25 °C	30 °C	50 °C	75 °C	25 °C	30 °C	50 °C	75 °C

APS/LDHs	3.89	25.62	6.58	1.55	2.05	2.09	1.86	0.40	0.53	0.54	0.48


Gene	ENSEMBL ID	ENSEMBL description

Acot7	ENSMUSG00000028937	acyl-CoA thioesterase 7 [Acc:MGI:1917275]

Ankrd13d	ENSMUSG00000005986	ankyrin repeat domain 13 family, member D [Acc:MGI:1915673]

Aplp1	ENSMUSG00000006651	amyloid beta (A4) precursor-like protein 1 [Acc:MGI:88046]

Atp1a3	ENSMUSG00000040907	ATPase, Na+/K+ transporting, alpha 3 polypeptide [Acc:MGI:88107]

Atp6v1a	ENSMUSG00000052459	ATPase, H+ transporting, lysosomal V1 subunit A [Acc:MGI:1201780]

Atp6v1d	ENSMUSG00000021114	ATPase, H+ transporting, lysosomal V1 subunit D [Acc:MGI:1921084]

Calm3	ENSMUSG00000019370	calmodulin 3 [Acc:MGI:103249]

Cdh13	ENSMUSG00000031841	cadherin 13 [Acc:MGI:99551]

Cyfip2	ENSMUSG00000020340	cytoplasmic FMR1 interacting protein 2 [Acc:MGI:1924134]

Dos	ENSMUSG00000035640	downstream of Stk11 [Acc:MGI:1354170]

Dusp26	ENSMUSG00000039661	dual specificity phosphatase 26 (putative) [Acc:MGI:1914209]

Gprasp1	ENSMUSG00000043384	G protein-coupled receptor associated sorting protein 1 [Acc:MGI:1917418]

Gria1	ENSMUSG00000020524	glutamate receptor, ionotropic, AMPA1 (alpha 1) [Acc:MGI:95808]

Grina	ENSMUSG00000022564	glutamate receptor, ionotropic, N-methyl D-asparate-associated protein 1 [Acc:MGI:1913418]

Hdac11	ENSMUSG00000034245	histone deacetylase 11 [Acc:MGI:2385252]

Kifap3	ENSMUSG00000026585	kinesin-associated protein 3 [Acc:MGI:107566]

Kns2	ENSMUSG00000021288	kinesin 2 [Acc:MGI:107978]

Ndrg4	ENSMUSG00000036564	N-myc downstream regulated gene 4 [Acc:MGI:2384590]

Pcdh17	ENSMUSG00000035566	protocadherin 17 [Acc:MGI:2684924]

Pfkm	ENSMUSG00000033065	phosphofructokinase, muscle [Acc:MGI:97548]

Phactr1	ENSMUSG00000054728	phosphatase and actin regulator 1 [Acc:MGI:2659021]

Pja2	ENSMUSG00000024083	praja 2, RING-H2 motif containing [Acc:MGI:2159342]

Ppp2r2c	ENSMUSG00000029120	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform [Acc:MGI:2442660]

Prkacb	ENSMUSG00000005034	protein kinase, cAMP dependent, catalytic, beta [Acc:MGI:97594]

Rogdi	ENSMUSG00000022540	rogdi homolog (Drosophila) [Acc:MGI:1913299]

Rusc1	ENSMUSG00000041263	RUN and SH3 domain containing 1 [Acc:MGI:1919546]

Scamp5	ENSMUSG00000040722	secretory carrier membrane protein 5 [Acc:MGI:1928948]

Slc25a4	ENSMUSG00000031633	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 [Acc:MGI:1353495]

Stx1b2	ENSMUSG00000030806	syntaxin 1B2 [Acc:MGI:1930705]

Sult4a1	ENSMUSG00000018865	sulfotransferase family 4A, member 1 [Acc:MGI:1888971]

Sv2a	ENSMUSG00000038486	synaptic vesicle glycoprotein 2 a [Acc:MGI:1927139]

Syngr3	ENSMUSG00000007021	synaptogyrin 3 [Acc:MGI:1341881]

Tspyl4	ENSMUSG00000039485	TSPY-like 4 [Acc:MGI:106393]

Vamp2	ENSMUSG00000020894	vesicle-associated membrane protein 2 [Acc:MGI:1313277]

Wbp2	ENSMUSG00000034341	WW domain binding protein 2 [Acc:MGI:104709]

Wsb2	ENSMUSG00000029364	WD repeat and SOCS box-containing 2 [Acc:MGI:2144041]

0710005I19Rik	ENSMUSG00000041141	RIKEN cDNA 0710005I19 gene [Acc:MGI:1918941]

2900002G04Rik	ENSMUSG00000041020	RIKEN cDNA 2900002G04 gene [Acc:MGI:1917474]

2900011O08Rik	ENSMUSG00000044117	RIKEN cDNA 2900011O08 gene [Acc:MGI:1914504]

5330410G16Rik	ENSMUSG00000035964	RIKEN cDNA 5330410G16 gene [Acc:MGI:1915187]

A030009H04Rik	ENSMUSG00000043419	RIKEN cDNA A030009H04 gene [Acc:MGI:1915359]


Generic name	Score	Information from DrugBankb	Information from other sources

Dexamethasone	22.1	An anti-inflammatory 9-fluoro-glucocorticoid.	Dexamethasone was reported to have a dramatic life-saving effect on people with cerebral malaria[44]. However, two subsequent placebo-controlled clinical trials failed to demonstrate clinical benefit[45,46].

Verapamil	21.5	A calcium channel blocker for hypertension, angina, and cluster headache prophylaxis.	A 1995 study[48] reported that verapamil reverses chloroquine resistance in the malaria parasite.

Quercetin	18.9	A flavonol found in plants, antioxidant.	A 2012 study[47] reported that quercetin had antiplasmodial activity.

Miconazole	16.5	An imidazole antifungal agent.	Many studies[39-43] have reported antimalarial activities of antifungal azole compounds.

Clotrimazole	15.9	An imidazole derivative with a broad spectrum of antimycotic activity.	Many studies[39-43] have reported antimalarial activities of azoles, including clotrimazole[43].

Cimetidine	15.5	For acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.	A 1997 study[49] reported synergism of cimetidine with antimalarial agents. It is ineffective when used alone.

Ketoconazole	15.2	For systemic fungal infections.	Many studies[39-43] have reported antimalarial activities of azoles, including ketoconazole[41].

Nifedipine	14.9	A calcium channel blocker for angina, hypertension, and Raynaud's phenomenon.

Tamoxifen	14.4	For breast cancer.

Clobetasol	14.4	For corticosteroid-responsive dermatoses of the scalp.


Variables

During the next 3 months	Measured Scale	Reliability coefficient

Self-efficacy	Very unlikely/very likely	.35a

I would be able to participate regularly in one or more physical activities even if...

 1-I have little free time

 2-I am not carrying excess body weight

Anticipated Regret	Very unlikely/very likely	.80b

During the next 3 months, if I do not participate in one or more physical activities...

 1-This will bother me

 2-I will regret it

 3-I will worry about it

Positive Feeling	Very unlikely/very likely	.52a

If I participate in one or more physical activities...

 1-I will be proud

 2-I would be satisfied

Moral Norm	Strongly disagree/strongly agree	.80b

 1-It is in my principles to participate in one or more physical activities

 2-To participate in one or more physical activities would be acting in accordance with my personal values

 3-It would be against my principles not to participate in one or more physical activities

Descriptive Norm

 1-A lot of people I know participate in one or more physical activities	Strongly disagree/strongly agree	.55a

 2-Among the 5 persons you know best, how many of them participate in one or more physical activities?	0 person to 5 people


Region of location	Upper East (Talensi- Nabdam and Kassena-Nankana West Districts)	Form of involvement (initiation, contribution of partners and management of the collaboration)	Advantages	Disadvantages

Interviews conducted	2 NGO2GHS	- Dubbed “CIMACS”- Initiated by GHS with CRS as an expert partner/and funder.- An MOU signed.- GHS supported with health facilities and personnel.- CRS trained Traditional Birth Attendants (TBAs) and community volunteers in social mobilization skills, provided logistics/incentives to attract pregnant women to deliver in health centres.- Program officers of CRS and focal persons of GHS shared equally in program management and regularly exchanged project progress information.- GHS held review meetings at sub-district, district and regional; quarterly, half yearly and annual basis, to evaluate progress with CRS/stakeholders.- CRS maintained monitoring and evaluation systems e.g. conduct of baseline studies; mid- term and end-of-project evaluations.- Quarterly and annual reports generated and shared with GHS/ donors as a requirement for continued support.- GHS required to keep records of CRS support (material and cash) and to render accounts periodically.	Improvement in maternal and child health indicators-e.g. antenatal registration (25 %); antenatal clinic attendance (22 %); exclusive breastfeeding (25 %); institutional deliveries (55 %); [35] and increased drug and immunization uptake.	- Occasional tendency for some GHS staff to provide somewhat unreliable data not useful for effective programming;- Occasional non-disclosure of full budget lines by GHS- Lack of synchronization of each other’s timetables;- CRS’ eagerness about timelines to demonstrate program performance to donors.

Driver of Collaboration	High under-five and maternal mortality recognized by GHS;- Need to attract pregnant women to deliver in government health centres rather than with TBAs.

Time Frame	2009–2011


	Nuevo Laredo	Matamoros	Veracruz

Iowa	Train: 1686 km	Train: 1800 km	Train: 220 kmWater: 2300 km

Ilinois	Train: 1637 km	Train: 1700 km	Train: 405 kmWater: 2300 km

Indiana	Train: 1833 km	Train: 1885 km	Train: 677 kmWater: 2300 km

Total 	1718 km + 650 km to the middle of the country	1795 km + 650 km to the middle of the country	434 km, train + 650 km to the middle of the country, Water: 2300 km


Model	LnL	AIC	AICc	ΔAICc	AICcWt

Legacy calibrated phylogeny

 Brownian motion single rate	123.77	−229.54	−203.82	221	0.00

 Brownian motion multiple rate	130.51	−219.03	−403.83	20.99	0.00

 Ornstein-Uhlbeck single rate	134.9	−239.91	240.09	664.91	0.00

 Ornstein-Uhlbeck multiple rate	141.01	−240.02	−424.82	0.00	0.99

 Ecological release	125.02	−220.04	259.96	684.78	0.00

 Release and radiate	135.67	−229.34	−414.14	10.68	0.00

 Ecological constraint	119.64	−209.28	270.72	695.54	0.00

 Radiation & ecological constraint	126.43	−210.86	−395.66	30.16	0.00

 Brownian motion/early burst	122.50	−225.01	−188.34	236.48	0.00

 Early burst/Brownian motion	53.24	−86.49	−49.83	374.99	0.00

Isthmus calibrated phylogeny

 Brownian motion single rate	123.94	−229.89	−204.17	223.12	0.00

 Brownian motion multiple rate	131.21	−220.42	−405.22	22.07	0.00

 Ornstein-Uhlbeck single rate	135.1	−240.19	239.81	667.10	0.00

 Ornstein-Uhlbeck multiple rate	142.24	−242.49	−427.29	0.00	0.99

 Ecological release	129.60	−229.20	250.80	678.09	0.00

 Release and radiate	135.48	−228.97	−413.77	13.52	0.00

 Ecological constraint	123.47	−216.94	263.05	690.34	0.00

 Radiation & ecological constraint	125.51	−209.02	−393.82	33.47	0.00

 Brownian motion/early burst	121.06	−222.13	−185.47	241.82	0.00

 Early burst/Brownian motion	121.78	−223.55	−186.89	240.40	0.00


Gene	Target sequence	ShRNA sequences

CXCR4-1	TCCTGGCCTTCATCAGTCT (6)	5′-GAT CCT CCT GGC CTT CAT CAG TCT TTC AAG AGA AGA CTG ATG AAG GCC AGG ATT TTT GGA AGC TAG GA-3′

CXCR4-2	TGCCCACCATCTACTCCAT (7)	5′-GAT CCT GCC CAC CAT CTA CTC CAT TTC AAG AGA ATG GAG TAG ATG GTG GGC ATT TTT GGA AGC TAG CA-3′

Negative control	AATCGCATAGCGTATGCCGTT (8)	5′-GAT CCA ATC GCA TAG CGT ATG CCG TTT TCA AGA GAA ACG GCA TAC GCT ATG CGA TTT TTT TGG AAG CTA GCA-3′


Background characteristics	Number (%)

Sex

 Male	86 (7.6)

 Female	975 (86.3)

 Missing	69 (6.1)

Age [mean, (SD)] years	28.8 (SD = 7.5)

Current marital status

 Never married	51 (4.6)

 Married (monogamous)	827 (73.9)

 Married (polygamous)	139 (12.4)

 Othera	102 (9.1)

Education status

 Never in school	166 (14.7)

 Some primary	803 (71.1)

 Above primary	151 (13.3)

 Missing	10 (0.9)

Employment status

 Salaried	778 (68.8)

 Unemployed	213 (18.9)

 Subsistence farmer	70 (6.2)

 Self-employed/wage earners	58 (5.1)

 Missing	11 (1.0)

Relationship to the child

 Parent	1043 (92.3)

 Kin or other	47 (4.2)

 Missing	40 (3.5)


VP1 NTa position	NTs in Sabin 2 and cVDPV2 sequences	iVDPV2 sequences	# sequences (iVDPV2) that exhibit variations

32	A	A or C	7

116	A	A or G	1

208	C	A or C	1

218	C	C or T	1

223	T	A or T	12

302	C	A or C	1

307	A	Deletionb	1

358	C	C or T	1

433	G	G or T	12

496	A	A or G	1

502	G	A or G	1

506	A	A or C	1

604	G	A or G	1

740	A	A or G	1

761	C	C or T	1

781	A	A or C or T	11C; 1 T


Description	E7 Clusters*	E14 Clusters*

Affected only by serum	13, 39	13, 39

Affected only by rcSF3	None	None

Serum and rcSF3 oppose one another	7, 14, 18, 34, 35, 38	14, 18, 34, 38

Serum and rcSF3 reinforce one another	0, 8, 49	0, 8, 10, 49

Serum and rcSF3 modulate one another	2, 5, 42	2, 5, 10, 47

Serum and rcSF3 substitute for one another	None	12

Gene expression increases with increasing TER	42	None

Gene expression decreases with increasing TER	None	None


Version		Parameter	Separation index	Reliability	Average infit mean square	Average outfit mean square

Malay	9-items	Person ability	2.84	0.89	1.00	1.01

Item difficulty	4.81	0.96	1.00	1.00

7-itemsa	Person ability	2.59	0.87	1.00	0.99

Item difficulty	4.97	0.96	1.00	0.98

Chinese	9-items	Person ability	2.59	0.87	1.00	1.01

Item difficulty	6.96	0.98	1.00	1.02

7-itemsa	Person ability	2.30	0.84	1.01	0.98

Item difficulty	5.28	0.97	1.00	0.98


Target	Forward primer	Reverse primer	Product length [bp]	Reference

HPRT	GAGAGCGTTGGGCTTACCTC	ATCGCTAATCACGACGCTGG	136	Rohm et al., 2015

PPARG	GTGCCAGTTTCGATCCGTAGA	GGCCAGCATCGTGTAGATGA	142	Rohm et al., 2015

FAS	CACAGATGATGACAGGAGATGG	TCGGAGTGAGGCTGGGTTGAT	205	Hewitt et al., 2004

LRP2	TGTACCAGAAAATGTGGAAAACC	GTGTCTTCTGTGGCAGTGTAGC	288	Lyons et al., 2003

IGF1R	GGAGTGTCCCTCAGGCTTCA	CATCGCCGCAGACTTTGG	89	Nef et al., 2003


Study	No. randomized	Characteristics of patients	BMI (SD)	Mean APACHE II score (SD)

LE	HE	LE	HE	LE	HE

Arabi et al. [21]	120	120	>18 years old	28.5 (7.4)	28.5 (8.4)	25.2 (7.5)	25.3 (8.2)

ICU >48 hours

Braunschweig et al. [22]	38	40	>18 years old	30.1 (8.9)	29.8 (9.3)	27.7 (7.9)	23.4 (9.3)

Medical or surgical ICU

ALI <24 hours

Charles et al. [23]	41	42	>18 years old	32.9 (2.0)	28.1 (0.9)	16.6 (0.9)	17.3 (0.8)

Artificial nutrition >48 hours

ICU >48 hours

Desachy et al. [24]	50	50	>18 years old	27 (5)	25 (3)	40 (11)1	42 (17)1

Medical or surgical ICU

Mechanical ventilation >72 hours

Peake et al. [25]	55	57	≥18 years old	26.2 (6.4)	27.8 (7.9)	22 (8.9)	23 (9.1)

Enteral nutrition ≥2 days

Mechanical ventilation

Rice et al. [26]	98	102	ICU admission	29.2 (10.2)	28.2 (9.4)	26.9 (8.1)	26.9 (6.6)

Mechanical ventilation >72 hours

Rice et al. [27]	508	492	ICU admission	29.9 (7.8)	30.4 (8.2)	92 (28)2	90 (27)2

ALI <48 hours

Mechanical ventilation >72 hours

Taylor et al. [28]	41	41	Head injury necessitating mechanical ventilation	N/A	N/A	143	143

Glasgow Coma Scale >3


Gene name	Primer sequence (5' to 3')	Position in ORF

APN1	3'Race	TGCGCTTCGAAGATTGGCTCACGATA	2018–2044

	5'Race	CTTCGATGAATGCCGAGACGCTGGAC	2122–2097

APN2	3'Race	CTTTGCTGCTGGTGCTATGGAGAACTGG	906–932

	5'Race	ACAGGGCTGACTTCATTTCCGAACCATT	1067–1040

APN3	3'Race	ATGCGTGAYGAYATGTACGGTAT	496–518

	5'Race	GCCAGGAGATAAGTTGACATTTTTGGGG	779–752

APN4	3'Race	TGGCTTTCCATGTGAGCGATTTTGTGC	728–754

	5'Race	CACACCGATTTCTGCAGCATACGAGTGC	849–822


Symbol	Definition	|Fold Change|(TM/TM-MSC)	Padj

MYOC	Myocilin, trabecular meshwork inducible glucocorticoid response	1374	6.97E-04

ANGPTL7	Angiopoietin-like 7	1189	1.48E-03

PCP4	Purkinje cell protein 4	656	2.33E-03

KRT13	Keratin 13	459	1.08E-03

SERPINA3	Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	447	3.75E-03

MYH11	Myosin, heavy chain 11, smooth muscle	429	1.00E-02

CDH23	Cadherin-like 23	420	6.97E-04

HLA-DRA	Major histocompatibility complex, class II, DR alpha	354	9.27E-04

PTGDS	Prostaglandin D2 synthase 21 kDa (Brain)	300	2.05E-02

FAM107A	Family with sequence similarity 107, member A	275	6.97E-04

HBB	Hemoglobin, beta	264	4.13E-03

C2orf40	Chromosome 2 open reading frame 40	239	8.31E-04

FCGBP	Fc fragment of IgG binding protein	231	9.27E-04

APOD	Apolipoprotein D	230	2.40E-02

CXADR	Coxsackie virus and adenovirus receptor	218	7.76E-04

TACSTD2	Tumor-associated calcium signal transducer 2	215	9.45E-04

H19	H19, imprinted maternally expressed transcript (non-protein coding)	210	1.38E-03

KRT5	Keratin 5	209	7.76E-04

CCL3L3	Chemokine (C-C motif) ligand 3-like 3	209	1.27E-03

VCAM1	Vascular cell adhesion molecule 1	199	2.49E-03


Session Topic	Protective Factor Targeted

Introduction and Program OverviewREADY resilience model, protective factors, warning signs of low resilience.

Activity Promotion (group 2 only)Activity benefits, national activity guidelines, step counting & pedometers, identifying preferences, goal setting, barriers & problem solving.	Physical activity

MindfulnessMindfulness vs mindlessness, mindfulness strategies.	Cognitive flexibilityPositive emotions

Defusion 1Thought fusion, identifying unhelpful thoughts, defusion strategies.	Cognitive flexibility

Defusion 2Observer self, defusion strategies.	Cognitive flexibility

AcceptanceAbout emotions, responding to emotions, about acceptance, acceptance strategies.	Positive emotions

Mid Program ReviewResilient and non resilient characteristics, activating and trouble shooting coping strategies.	Active coping

Life Values and Meaningful ActionAbout values, value identification, meaningful action.	Life meaning

Social ConnectednessTypes of support, support responses, active and reflective listening, barriers to social connectedness.	Social support

Relaxation and Pleasant ActivitiesActive relaxation exercises, progressive muscle relaxation exercises, pleasurable activities.	Positive emotions

Review and Planning for the FutureResilient and non resilient characteristics, activating and trouble shooting coping strategies.	Active coping


Types	Relative	Personal	DNP	All

EL	6	0	0	6

FL	5	19	6	30

BMB	0	8	0	8

Sum	11	27	6	44


First author [Reference]	Bjerregaard [[28]]	Pelletier [[29]]	Elo [[31]]	Berger [[30]]

Country	Denmark	Canada	Finland	Israel

Year	1991	1998	1979	1990

WB income group	High	High	High	High

Comparators	1. Vaccinate 15-month and 12-yr-olds	1. 1-dose child vaccination campaign	1. Vaccinate 13-yr-olds & post-partum women	1. Vaccinate children from 1 – 12 years

 	2. Vaccinate only 15-month-olds	2. 2-dose child vaccination campaign	2. Vaccinate 13-yr-olds & 1-yr-olds	2. Vaccinate only 12-yr-olds (routine)

 	 	3. 1-dose child vaccination	3. Vaccinate only 1-yr-olds over 20 years

 	 	4. 2-dose child vaccination

Perspective	Societal*	Societal*	Societal*	NR

Cost components measured	OP visits; prescriptions; hospitalizations; vaccines	OP visits; hospitalizations; laboratory tests; nursing home care; special education; indirect costs (lost productivity for illness, disability and premature death)	Fetal loss; fetal damage; annual costs; long-term costs	Vaccine; vaccination side effects; serology; OP visits; hospitalizations; hearing aids; mothers’ work loss;

Method of cost estimation	Micro-costing	Micro-costing; Lifetime earnings (for indirect costs)	Top-down costing based on Delphi panel	Micro-costing

Method of benefits estimation	Averted costs	Averted costs	Averted costs	Averted costs

Time period for costs and benefits	20 years	Lifetime	30 years	13 years

Discounting (Rate)	NR	Yes (5%)	Yes (6%)	Yes (5 and 10%)

Results—Benefit-cost ratio	1. 3	1. 2.6	1. 10	1. 1.1

 	2. 2	2. 2.9	2. 3	2. 1.8

 	 	3. 3.6	3. 6

 	 	4. 4.3

Stated conclusion	Vaccinating both age groups is preferable	The benefits of a second dose outweigh the costs	Vaccinating 13-yr-old girls and postpartum women was preferable	Vaccinating infants and adolescent girls is preferable

Sponsor	NR	LCDC	NR	NR


Organ	OA

Fifth leaf	−0.16 ± 0.07

Awn	0.36 ± 0.07

Lemma	0.42 ± 0.05

Palea	0.30 ± 0.04


	WT 4dpp	KO 4dpp	WT 9dpp	KO 9dpp	WT adult	KO adult

≥2 apoptotic cells per tubule	1.4	3.4	17.6	36.4	28.0	30.5

Total number of tubules counted	300	300	300	300	201	201

Number of testes used	4	4	4	4	2	4

P (Fisher's exact test	0.17		0.0006		0.8


S. No.	Name	Description

1.	Circular Fingerprint	Circular fingerprint is based on CDK’s [31] circular fingerprinter and is functionally equivalent to ECFP-2 [43]

2.	Extended Fingerprint	Functionally equivalent to ExtendedFingerprinter of CDK [31]. This fingerprint is unique from the standard form since it accounts for ring systems. Default length size is 1024 bits.

3.	Substructure Fingerprint	This is a structural key type fingerprint which considers assessment of 307 different substructures and is based on KlekotaRothFingerprinter [44] in CDK.

4.	Enhanced Fingerprint	An in-house developed improvised extended fingerprint which accounts for stereochemistryand charges on molecules.


Elution methods	Elution liquid-solid ratio (mL/g)	Elution time (h)	Elution capacity (Q, mg/g)

Soxhlet extraction	100	24	547

Ultrasonic extraction	40	1	815

Microwave-assisted extraction	40	5	326


Node	Description	Degree

UBC	ubiquitin C	739

EGFR	epidermal growth factor receptor	157

MDM2	MDM2 proto-oncogene	153

TP53	tumor protein p53	152

APP	amyloid beta precursor protein	149

HSP90AA1	heat shock protein 90 alpha family class A member 1	149

EP300	E1A binding protein p300	135

SUMO1	small ubiquitin-like modifier 1	130

GRB2	growth factor receptor bound protein 2	128

SRC	SRC proto-oncogene, non-receptor tyrosine kinase	126

CTNNB1	catenin beta 1	125

FN1	fibronectin 1	123

YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	122

ESR1	estrogen receptor 1	110

HSP90AB1	heat shock protein 90 alpha family class B member 1	107

HDAC1	histone deacetylase 1	100

AKT1	AKT serine/threonine kinase 1	96

AR	androgen receptor	92

MAPK1	mitogen-activated protein kinase 1	88

CUL7	cullin 7	87

MYC†	v-myc avian myelocytomatosis viral oncogene homolog	87


Parameter	Body weight (g)	Food Intake (Kcal)	Glucose (mM)	Ketones (mM)	Seizure Susceptibility

Body weight (g)	1.000

Food Intake (Kcal)	0.488*	1.000

Glucose (mM)	0.509*	0.382*	1.000

Ketones (mM)	-0.379*	-0.379*	-0.429*	1.000

Seizure Susceptibility	0.512*	0.464*	0.616*	-0.510*	1.000


Comorbidity	Prevalence

N = 14,005	(n)	(%)	95% CI

Mental health condition	5,401	38.6%	(37.8% to 39.4%)

Physical conditions:

Myocardial infarction	174	1.2%	(1.1% to 1.4%)

Congestive heart disease	233	1.7%	(1.5% to 1.9%)

Chronic obstructive pulmonary disease	1,106	7.9%	(7.5% to 8.3%)

End stage renal disease	223	1.6%	(1.4% to 1.8%)

Peripheral vascular disease	72	0.5%	(0.4% to 0.6%)

Asthma	1,780	12.7%	(12.2% to 13.3%)

Diabetes	1,167	8.3%	(7.9% to 8.8%)

Hypertension	2,093	14.9%	(14.4% to 15.5%)

Stroke	173	1.2%	(1.1% to 1.4%)

At least one physical condition	4820	34.4%	(33.6% to 35.2%)

Physical-mental health multimorbidity	2,174	15.5%	(14.9% to16.1%)

Multimorbidity (at least two physical conditions)	1,508	10.8%	(10.3% to 11.3%)


Phytochemical	Detection system	Observation	Result

Coumarin	365 nm	Blue spot	+

Flavonoids	5% AlCl3	Yellow spot	+

Tannin	2% FeCl3	Greenish Black spot	+

Saponin	10% Vanillin (Ethanol)	Violet and yellow	+

Monoterpene alcohol, Bitter principle saponin	Vanillin-H2SO4	Blue	+

Triterpene and steroid	Lieberman-Buchard’s reagent	Brown and yellow spots	+


Classification result

Actual result	 Forecast result

P	N

P	TP	FN

N	FP	TN


Annotation Clusters	Official Symbol

Vascular development	Eph2, Chd7, Ereg, Foxc1, Gja1, Itgav, Lepr, Nus1, Pdpn,Prox1, S1pr1, Socs3, Zfp36l1

Embryonic morphogenesis	Eph2, Chd7, Chst11, Foxc1, Hes1, Il10, Mmp13, Pbx1,Prox1, Socs3, Spry2, Jag2

Sexual reproduction	Bcl6, Bcl2l11, Crem, Calca, Cadm1, Ereg, Fst, Foxc1,Jag2, Lepr, Pvrl3, Rgs2, Stat3

Response to wounding, Inflammatory and Defense responses	Bmp6, Cd14, Calca, Ddah2, Entpd1, Gja1, Hdac5, Il1f6,Il10, Saa1, Saa2, Stat3, Thbd, Thbs1

Growth factors, GF activity	Areg, Bmp6, Chst11, Csf3, Ereg, Foxc1, Gja1, Hgf, Inhbb,Jag2

DNA binding, Transcription regulation	Arid3b, Bcl6, Bach2, Gata2, Lhx8, Mxd1, Mxi1, Setbp1,Thap2, Crem, Chd7, Dedd2, Foxc1, Hes1, Hdac5, Lrrfip1,Nr4a2, Pbx1, Prox1, Runx2, Stat3, Fosl2, Sbno2, Tshz3, Tle1,Mafb, Zfp36, Zfp36l1

Disulfide bond	Nt53, Abca1, Cd14, Cd80, Edil3, Eph2, Gpr35, Areg,Antxr2, Bmp6, Calca, Cacna1d, Cadm1, Cbln3, CxCr7, Csf3,Entpd1, Ereg, Fst, Gja1, Havcr2, Hgf, Inhbb, Itgav, Il10,Jag2, Lepr, Lifr, Man1a, Mmp13, Mmp3, Mpzl1, Niacr1, Pla1a,Pvrl3, Ptger2, Lpar6, Ramp3, Sema6d, Tnfaip6, Thbd, Thbs1,Trem1, Tnfrsf9


Gene	Ensembl ID	Reference	Sites found by RNA-seq for	Sites found by HTA for	Concordant

exons	junctions	exons	junctions

TP63	ENSG00000073282	Lo Iacono et al. [57]	6	10	2	27	No

TP73	ENSG00000078900	Lo Iacono et al. [57]	0	2	2	6	No

CD44	ENSG00000026508	Wang et al. [58]	34	32	19	43	No

HLA-G	ENSG00000204632	Yan et al. [59]	2	0	0	0	No

POSTN	ENSG00000133110	Morra et al. [60]	3	5	1	7	No

RUNX1	ENSG00000159216	Ito et al. [61]	8	2	18	13	Yes


Field	Code	Character	Item amount	Scores (R)	Calculation method

Physical function	PF	Function	5	3	(Q1 + Q2 + Q3 + Q4 + Q5)/5

Role function	RF	Function	2	3	(Q6 + Q7)/2

Emotional function	EF	Function	4	3	(Q21 + Q22 + Q23 + Q24)/4

Cognitive function	CF	Function	2	3	(Q20+ Q25)/2

Social function	SF	Function	2	3	(Q26 + Q27)/2

Global QOL	QL		2	6	(Q29 + Q30)/2

Fatigue	FA	Symptom	3	3	(Q10 + Q12 + Q26)/3

Nausea and vomiting	NV	Symptom	2	3	(Q14 + Q15)/2

Pain	PA	Symptom	2	3	(Q9 + Q19)/2

Dyspnea	DY	Symptom	1	3	Q8

Sleep disturbance	SL	Symptom	1	3	Q11

Appetite loss	AP	Symptom	1	3	Q13

Constipation	CO	Symptom	1	3	Q16

Diarrhea	DI	Symptom	1	3	Q17

Financial difficulties	FI	Symptom	1	3	Q28


Primer name	Assay	Sequence (5′-3′)	Exon position	Target gene	Amplicon sizes (bp)

GHRL-1 F	RT-PCR	TTTCTGAGCCCTGAACATCAG	1	GHRL	305 canonical (wild-type) preproghrelin

GHRL-4R		GAGAACAGACAGGTGGTTGG	4

GHRL-5OF	RACE	ATGAATGAACACTGCGTTTGCT	N/A	GHRL	174

GHRL-5OR		CAGTTTCTGATGTTCAGGGCTC	1

GHRL-5IF	RACE	GAACACTGCGTTTGCTGGCT	N/A	GHRL	130

GHRL-5IR		GGCCAAGTCCATCCAGAGCA	1

GHRL-2F	qRT-PCR	CTAAGAAGCCGTCAGGCAGACT	2	GHRL (preproghrelin)	153

GHRL-2R		GGGACTGAGCCCCTGACA	3

GHRL1_3F	qRT-PCR	CAGAAACTGCAGTTCAATGC	1 / 3	GHRL (Δex2 preproghrelin)	224

GHRL-4R		CACGTGGTCTCGGAAGTGT	4

GHRL1_4F	qRT-PCR	CTGCAGAAACCCTGGCTGA	1 / 4	GHRL (Δex2,3 preproghrelin)	109

GHRL-4R		CACGTGGTCTCGGAAGTGT	4

GOAT-mF	qRT-PCR	GGTTTCAAGCTCGAGTTGAAGG	N/A	MBOAT4 (GOAT)	212

GOAT-mR		AGTAGGTGAGTTTGAAGAGCCC

GAPDH-F	qRT-PCR	CCTGGAGAAACCTGCCAAGT	N/A	GAPDH	209

GAPDH-R		GCCAAATTCATTGTCGTACCA


 	CD8+T cells	CD4+T cells	References

Characteristics	Decreased HBV-specific CD8+ T cells; impaired cytotoxicity (IL-2, IFN-γ and TNF-α); increased inhibitory receptors including PD-1, TIM-3, CTLA-4 and 2B4	Impaired proliferation without obvious defect in Th-1-type cytokines; high PD-1 and low expression of CTLA-4, TIM-3, KLRG1 and 2B4	1, 9, 11, 25, 26, 27, 28, 106, 107

Evidence for immunotherapy	Blockade of the PD-1/PD-L1 pathway restored proliferation and function of HBV-specific CD8+ T cells; blockade of CD244 or its ligand CD48 may recover proliferation, cytokine production and cytotoxicity of exhausted HBV-specific CD8+ T cells; blockade of CTLA-4 was able to increase the proliferation of IFN-γ-producing HBV-specific CD8+ T cells; by blocking Tim-3/galectin-9 interactions, expansion of HBV-specific CD8+ T cells was enhanced, which were able to produce cytokines and mediate cytotoxicity	PDGF-BB inhibited CD4+ T-cell proliferation; antibody specific for the PDGF-B chain was able to reduce the development of liver fibrosis; neutralization of PD-L1/2 was able to improve the ability of CD4+ T cells to produce Th-1 cytokines	11, 26, 35, 47, 49, 51, 61, 62, 63, 106, 107


 	Mucosal Biopsy	Surgical Resection

Actin	Positive	Positive

Vimentin	Positive	Positive

Bcl-2	Positive	Positive

CD138	Positive	Not done

Calponin	Not done	Positive

Collagen type IV	Not done	Pericellular net-like pattern

EMA	Not done	Focal Positive

AE1/3	Negative	Focal Positive

Cam5.2	Negative	Negative

CK20	Negative	Not done

CD56	Negative	Negative

Desmin	Negative	Negative

S100	Negative	Negative

MPO	Negative	Not done

CD20	Negative	Not done

CD21	Negative	Not done

CD99	Negative	Not done

CD30	Negative	Not done

C-Kit	Negative	Negative

DOG1	Negative	Negative

PLAP	Negative	Not done

WT1	Not done	Negative

CD10	Not done	Negative

Chromogranin	Not done	Negative

Synaptophysin	Not done	Patchy Positive

NSE	Not done	Focal Positive

Myogenin	Not done	Negative

EWS translocation	Not done	Negative

SYT translocation	Not done	Negative

CIC-DUX4 translocation	Not done	Negative


Area	Median	Range	Inter Quartile Range (IQR)	Z*	P value

Shenzhen (N = 1,826)	6	0-8	4-7	-12.547	<0.001

Xiuning (N = 2,572)	5	0-8	3-6


Cell Line	MTT Assay	CellTiter-Glo Assay

MCF10a	ND	ND

MCF-7	24±2	27±2

T47D	26±2	28±3

MDA-MB-231	30±3	30±3


Sno	Sub-District	Health Facility	ANC Attendance	% of Total Attendance	Quota Sampled

Wa Municipality

 1	Kambale Sub	Kambale HC	697	5.64	14

 2	Bamahu Sub	Bamahu HC	407	3.30	8

 3	Charingu Sub	Charingu HC	282	2.28	6

 4	Busa Sub	Busa HC	279	2.26	5

 5	Wa Sub	Wa Reg. Hospital	8942	10.87	180

 6	Wa sub	Wa Central HC	1341	72.50	27

 7	Charia Sub	Dobile CHPS	392	3.18	8

 Total	12,340	100.00	248

Lawra District

 8	Eremon Sub	Eremon HC	107	8.89	19

 9	Lawra Sub	Lawra Dist. Hosp	715	59.43	125

 10	Lawra Sub	Lawra Sub HC	28	2.33	5

 11	Babile Sub	Babile Polyclinic	194	16.13	34

 12	Domwini Sub	Domwini HC	42	3.49	7

 13	Zambo Sub	Zambo HC	117	9.73	20

 Total	1203	100.00	210